{
  "usdmVersion": "4.0",
  "generatedAt": "2026-01-05T13:50:06.308539",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "ccc5d391-cb2e-4f33-aaeb-e233252575b3",
    "instanceType": "Study",
    "versions": [
      {
        "id": "9335aaef-95f2-4d32-8314-0cfd77a17cd7",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "d8d742e8-9df8-4a9a-85bd-7ff177049f5a",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "c46d489d-7028-4592-adff-7c110fd55bca",
              "standardCode": {
                "id": "142572b3-9e7b-414e-a08b-ad4ecef5a638",
                "code": "Open Label",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Open Label",
                "instanceType": "Code"
              },
              "instanceType": "AliasCode"
            },
            "randomizationType": {
              "code": "Randomized"
            },
            "arms": [
              {
                "id": "61a0fef0-1271-4dd1-87a7-23441ad4bc4d",
                "name": "LY900018 (Nasal Glucagon)",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Single 3-mg dose of LY900018 administered nasally during one of the two treatment periods.",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "a70671f3-847a-4774-8479-945e7d1f84ad",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              },
              {
                "id": "064a748a-1928-4060-8be0-14c76faf6f05",
                "name": "Intramuscular Glucagon (IMG)",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Single 1-mg dose of Intramuscular Glucagon (GlucaGen) administered via IM injection during one of the two treatment periods.",
                "type": {
                  "id": "C174267",
                  "code": "C174267",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.12e",
                  "decode": "Active Comparator Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "d11f0276-b482-4e38-835b-ce3aa1c8a83a",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              }
            ],
            "studyCohorts": [
              {
                "id": "0aae858f-491b-43c7-b138-58ee08210fef",
                "name": "Type 1 Diabetes Mellitus (T1DM) Patients",
                "instanceType": "StudyCohort",
                "characteristic": "Patients with a diagnosis of T1DM for at least 1 year on daily insulin therapy."
              },
              {
                "id": "8ef63c78-77ba-43e9-91f0-c5d41abac0c0",
                "name": "Type 2 Diabetes Mellitus (T2DM) Patients",
                "instanceType": "StudyCohort",
                "characteristic": "Patients with a diagnosis of T2DM for at least 1 year on daily insulin therapy."
              }
            ],
            "studyCells": [
              {
                "id": "9a3bf258-6868-44c2-a166-0d0be8c33ab2",
                "armId": "61a0fef0-1271-4dd1-87a7-23441ad4bc4d",
                "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "b3a4f39a-32e5-4c09-a526-0845d7b0b65d",
                "armId": "61a0fef0-1271-4dd1-87a7-23441ad4bc4d",
                "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "93910f74-383b-411f-b134-717d11f42d3a",
                "armId": "61a0fef0-1271-4dd1-87a7-23441ad4bc4d",
                "epochId": "3d64d9a8-6953-4f11-bdbf-6d65150c86b4",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "1d4cc754-fe5f-4d95-a7af-7d8b143d4de3",
                "armId": "61a0fef0-1271-4dd1-87a7-23441ad4bc4d",
                "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "9998df03-e9b8-49ed-b381-fdbff46599a4",
                "armId": "61a0fef0-1271-4dd1-87a7-23441ad4bc4d",
                "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "04b2f94e-e127-466c-a976-c542a56c9775",
                "armId": "61a0fef0-1271-4dd1-87a7-23441ad4bc4d",
                "epochId": "7d335965-fac7-4587-81d4-8e1fe13187dd",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "7d5e2b1e-a272-4450-960a-c9544dc842a7",
                "armId": "064a748a-1928-4060-8be0-14c76faf6f05",
                "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "efa6adfb-8bef-4944-a3d9-56a007b21147",
                "armId": "064a748a-1928-4060-8be0-14c76faf6f05",
                "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "c412ed97-6298-40e1-b4f3-3109cf076bb4",
                "armId": "064a748a-1928-4060-8be0-14c76faf6f05",
                "epochId": "3d64d9a8-6953-4f11-bdbf-6d65150c86b4",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "0e9c71f9-e14a-4c33-bb61-e9921548ac65",
                "armId": "064a748a-1928-4060-8be0-14c76faf6f05",
                "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "6b308649-f1fc-46e5-b6c6-2cc065f1ae00",
                "armId": "064a748a-1928-4060-8be0-14c76faf6f05",
                "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "0836222b-0a4f-4cb0-8b7c-4232aa236cb8",
                "armId": "064a748a-1928-4060-8be0-14c76faf6f05",
                "epochId": "7d335965-fac7-4587-81d4-8e1fe13187dd",
                "elementIds": [],
                "instanceType": "StudyCell"
              }
            ],
            "eligibilityCriteria": [
              {
                "id": "6cd77494-3391-462d-a007-7159325ef080",
                "identifier": "[1]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "4dafcf5f-11d2-468c-abf4-97d3017dff4e",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 1",
                "nextId": "4d0505df-c6c7-44d1-acda-602a9714ce5b"
              },
              {
                "id": "4d0505df-c6c7-44d1-acda-602a9714ce5b",
                "identifier": "[2]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "00596f71-9604-4622-b110-5da85ac18704",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 2",
                "previousId": "6cd77494-3391-462d-a007-7159325ef080",
                "nextId": "c4ffc583-b5ac-42e7-ad46-481409be09ec"
              },
              {
                "id": "c4ffc583-b5ac-42e7-ad46-481409be09ec",
                "identifier": "[3]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "3dca4c67-73d3-4c1a-9618-48d8c066e263",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 3",
                "previousId": "4d0505df-c6c7-44d1-acda-602a9714ce5b",
                "nextId": "6914cc1b-f109-4e07-9e0b-b29031172dc2"
              },
              {
                "id": "6914cc1b-f109-4e07-9e0b-b29031172dc2",
                "identifier": "[4]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "f7716093-e22f-4db2-9509-52bc34858d03",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 4",
                "previousId": "c4ffc583-b5ac-42e7-ad46-481409be09ec",
                "nextId": "4a14269b-662d-4cc4-8d46-aba435b9354a"
              },
              {
                "id": "4a14269b-662d-4cc4-8d46-aba435b9354a",
                "identifier": "[5]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9e270e37-9cc1-4028-b2c8-afc868b1a59f",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 5",
                "previousId": "6914cc1b-f109-4e07-9e0b-b29031172dc2",
                "nextId": "a98ac1c8-8732-4a72-be50-2e399557aac3"
              },
              {
                "id": "a98ac1c8-8732-4a72-be50-2e399557aac3",
                "identifier": "[6]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "5cbb9ea9-7d38-45de-872d-e8af4623b868",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 6",
                "previousId": "4a14269b-662d-4cc4-8d46-aba435b9354a",
                "nextId": "7d53db1c-ec86-490d-ace8-c6a358eba4fb"
              },
              {
                "id": "7d53db1c-ec86-490d-ace8-c6a358eba4fb",
                "identifier": "[7]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "7a8454a8-1084-4296-b25f-f3c847ea4820",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 7",
                "previousId": "a98ac1c8-8732-4a72-be50-2e399557aac3",
                "nextId": "fad07218-989f-4ab0-ab52-bb4ffc7ee897"
              },
              {
                "id": "fad07218-989f-4ab0-ab52-bb4ffc7ee897",
                "identifier": "[8]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "4714e10a-9052-4df6-8f5e-be77c064d27e",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 8",
                "previousId": "7d53db1c-ec86-490d-ace8-c6a358eba4fb",
                "nextId": "5b6f6098-1f82-48ad-8390-5fdd1759b78e"
              },
              {
                "id": "5b6f6098-1f82-48ad-8390-5fdd1759b78e",
                "identifier": "[9]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "74e45f0f-d612-490f-a53a-d51be516dfd7",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 9",
                "previousId": "fad07218-989f-4ab0-ab52-bb4ffc7ee897",
                "nextId": "52aee12a-0f32-4dbc-987b-9f41219a41e0"
              },
              {
                "id": "52aee12a-0f32-4dbc-987b-9f41219a41e0",
                "identifier": "[10]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a179a55f-5f37-4e9f-8c7b-eb467ef43ab6",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 10",
                "previousId": "5b6f6098-1f82-48ad-8390-5fdd1759b78e"
              },
              {
                "id": "0b09b257-0d6c-4cd4-a82e-10615664d0df",
                "identifier": "[11]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "42d532d2-1862-445f-924a-f82b07e7e45f",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 11",
                "nextId": "5f438167-7465-4503-95a3-ea306755738c"
              },
              {
                "id": "5f438167-7465-4503-95a3-ea306755738c",
                "identifier": "[12]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "6183ac6b-8b5b-487b-a44a-a41f6cdaa1c4",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 12",
                "previousId": "0b09b257-0d6c-4cd4-a82e-10615664d0df",
                "nextId": "efc60c3e-9007-48e3-9dfc-9f32c060ef5b"
              },
              {
                "id": "efc60c3e-9007-48e3-9dfc-9f32c060ef5b",
                "identifier": "[13]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "60bb90fd-49fe-4b08-9d98-74a82136b7e1",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 13",
                "previousId": "5f438167-7465-4503-95a3-ea306755738c",
                "nextId": "bf3b1632-9b75-4412-b110-52a69118901d"
              },
              {
                "id": "bf3b1632-9b75-4412-b110-52a69118901d",
                "identifier": "[14]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "fb1e0cc6-572a-41cb-b24b-65d36c8134fe",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 14",
                "previousId": "efc60c3e-9007-48e3-9dfc-9f32c060ef5b",
                "nextId": "b861e8fa-bde9-496a-9e5e-2f87be075d18"
              },
              {
                "id": "b861e8fa-bde9-496a-9e5e-2f87be075d18",
                "identifier": "[15]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "d2cfb060-7e26-45aa-88de-a534164bde02",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 15",
                "previousId": "bf3b1632-9b75-4412-b110-52a69118901d",
                "nextId": "e616f1a9-1016-4c41-aa38-8a4889bff015"
              },
              {
                "id": "e616f1a9-1016-4c41-aa38-8a4889bff015",
                "identifier": "[16]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "f861389d-1aa3-4a5a-8402-0b34818b4d37",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 16",
                "previousId": "b861e8fa-bde9-496a-9e5e-2f87be075d18",
                "nextId": "9788f959-e35c-4822-9f73-9e342c7a5d3e"
              },
              {
                "id": "9788f959-e35c-4822-9f73-9e342c7a5d3e",
                "identifier": "[17]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "893e4390-f5f2-4ea8-b4c9-95637c6e7222",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 17",
                "previousId": "e616f1a9-1016-4c41-aa38-8a4889bff015",
                "nextId": "2fa6f4f2-850e-492c-adbd-e272fde0a423"
              },
              {
                "id": "2fa6f4f2-850e-492c-adbd-e272fde0a423",
                "identifier": "[18]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a303ef7b-d3ed-46b0-b21a-fd95075355a4",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 18",
                "previousId": "9788f959-e35c-4822-9f73-9e342c7a5d3e",
                "nextId": "1cccbb7d-7165-49e7-b80f-a3005ec41862"
              },
              {
                "id": "1cccbb7d-7165-49e7-b80f-a3005ec41862",
                "identifier": "[19]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a5624993-81f9-4a6a-a46f-b6a507907b8e",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 19",
                "previousId": "2fa6f4f2-850e-492c-adbd-e272fde0a423",
                "nextId": "46f5d4c8-479d-4fa7-8b1e-18f18baad4e5"
              },
              {
                "id": "46f5d4c8-479d-4fa7-8b1e-18f18baad4e5",
                "identifier": "[20]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "bc3f661e-e812-4b54-8322-c5db92895d14",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 20",
                "previousId": "1cccbb7d-7165-49e7-b80f-a3005ec41862",
                "nextId": "1dc9ea22-803b-4d99-bc86-0ac967f38f33"
              },
              {
                "id": "1dc9ea22-803b-4d99-bc86-0ac967f38f33",
                "identifier": "[21]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "08b4fa24-04cd-440a-afee-1ce71b208555",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 21",
                "previousId": "46f5d4c8-479d-4fa7-8b1e-18f18baad4e5",
                "nextId": "2c475c8b-f1ab-4277-aa87-09d9efe7610e"
              },
              {
                "id": "2c475c8b-f1ab-4277-aa87-09d9efe7610e",
                "identifier": "[22]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "38ecdb92-8dbf-4213-b86a-2fd434673aaf",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 22",
                "previousId": "1dc9ea22-803b-4d99-bc86-0ac967f38f33",
                "nextId": "2e438b01-f4fe-4ea3-9576-bcbf0ee1b946"
              },
              {
                "id": "2e438b01-f4fe-4ea3-9576-bcbf0ee1b946",
                "identifier": "[23]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ddf27d26-5484-4277-aad0-84752e47f201",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 23",
                "previousId": "2c475c8b-f1ab-4277-aa87-09d9efe7610e",
                "nextId": "0ed88efb-c71d-4a22-82c0-383832b2edda"
              },
              {
                "id": "0ed88efb-c71d-4a22-82c0-383832b2edda",
                "identifier": "[24]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "bbb8d445-cac5-4dbd-9230-fac5c83f9273",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 24",
                "previousId": "2e438b01-f4fe-4ea3-9576-bcbf0ee1b946",
                "nextId": "d70b48b2-abbf-4dd9-a5f6-3ea68485353f"
              },
              {
                "id": "d70b48b2-abbf-4dd9-a5f6-3ea68485353f",
                "identifier": "[25]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "06b96421-9a33-44a4-b8c9-57d1ff35f3bf",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 25",
                "previousId": "0ed88efb-c71d-4a22-82c0-383832b2edda",
                "nextId": "57ce07e1-e5f8-4fc5-b9f6-ac7584e570cc"
              },
              {
                "id": "57ce07e1-e5f8-4fc5-b9f6-ac7584e570cc",
                "identifier": "[26]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "04fcfe02-bf45-4545-81a4-ce13227ff1f0",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 26",
                "previousId": "d70b48b2-abbf-4dd9-a5f6-3ea68485353f",
                "nextId": "316102ae-9ee6-438d-a416-43fcf091bcdb"
              },
              {
                "id": "316102ae-9ee6-438d-a416-43fcf091bcdb",
                "identifier": "[27]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "8e028651-501b-4e32-b390-b756896dfce1",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 27",
                "previousId": "57ce07e1-e5f8-4fc5-b9f6-ac7584e570cc",
                "nextId": "203cce98-fc22-43d9-af33-b7889e34a1c6"
              },
              {
                "id": "203cce98-fc22-43d9-af33-b7889e34a1c6",
                "identifier": "[28]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9ff3e1ff-47db-4446-801c-950f94289618",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 28",
                "previousId": "316102ae-9ee6-438d-a416-43fcf091bcdb",
                "nextId": "a7c0ba0b-e7b3-430a-aa4c-6186a287c7db"
              },
              {
                "id": "a7c0ba0b-e7b3-430a-aa4c-6186a287c7db",
                "identifier": "[29]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ce9ae98b-7e2b-4b56-9db6-3a1ae3d67c7e",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 29",
                "previousId": "203cce98-fc22-43d9-af33-b7889e34a1c6",
                "nextId": "c03b2427-d0b6-4fec-9442-a7d8b230386b"
              },
              {
                "id": "c03b2427-d0b6-4fec-9442-a7d8b230386b",
                "identifier": "[30]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9318d9da-5d74-44db-9fd4-c13cf143f121",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 30",
                "previousId": "a7c0ba0b-e7b3-430a-aa4c-6186a287c7db",
                "nextId": "13b18619-51a7-4fd7-8461-855da071041a"
              },
              {
                "id": "13b18619-51a7-4fd7-8461-855da071041a",
                "identifier": "[31]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "721ab8c4-9b5f-4608-a0ce-47411446ef09",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 31",
                "previousId": "c03b2427-d0b6-4fec-9442-a7d8b230386b",
                "nextId": "0d19ed30-0095-4e3e-94c7-c5437ba39bf7"
              },
              {
                "id": "0d19ed30-0095-4e3e-94c7-c5437ba39bf7",
                "identifier": "[32]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "bb159da5-fe2b-4e42-9922-658c1ba111df",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 32",
                "previousId": "13b18619-51a7-4fd7-8461-855da071041a",
                "nextId": "a729923e-f63d-479d-be92-7a326025eeb1"
              },
              {
                "id": "a729923e-f63d-479d-be92-7a326025eeb1",
                "identifier": "[33]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "98060254-5a3c-4978-b23e-d5ee13f3da59",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 33",
                "previousId": "0d19ed30-0095-4e3e-94c7-c5437ba39bf7"
              }
            ],
            "population": {
              "id": "dbcb25e3-aaf8-4cce-a558-3e0f53d85b7d",
              "name": "Study Population",
              "includesHealthySubjects": false,
              "criterionIds": [
                "6cd77494-3391-462d-a007-7159325ef080",
                "4d0505df-c6c7-44d1-acda-602a9714ce5b",
                "c4ffc583-b5ac-42e7-ad46-481409be09ec",
                "6914cc1b-f109-4e07-9e0b-b29031172dc2",
                "4a14269b-662d-4cc4-8d46-aba435b9354a",
                "a98ac1c8-8732-4a72-be50-2e399557aac3",
                "7d53db1c-ec86-490d-ace8-c6a358eba4fb",
                "fad07218-989f-4ab0-ab52-bb4ffc7ee897",
                "5b6f6098-1f82-48ad-8390-5fdd1759b78e",
                "52aee12a-0f32-4dbc-987b-9f41219a41e0",
                "0b09b257-0d6c-4cd4-a82e-10615664d0df",
                "5f438167-7465-4503-95a3-ea306755738c",
                "efc60c3e-9007-48e3-9dfc-9f32c060ef5b",
                "bf3b1632-9b75-4412-b110-52a69118901d",
                "b861e8fa-bde9-496a-9e5e-2f87be075d18",
                "e616f1a9-1016-4c41-aa38-8a4889bff015",
                "9788f959-e35c-4822-9f73-9e342c7a5d3e",
                "2fa6f4f2-850e-492c-adbd-e272fde0a423",
                "1cccbb7d-7165-49e7-b80f-a3005ec41862",
                "46f5d4c8-479d-4fa7-8b1e-18f18baad4e5",
                "1dc9ea22-803b-4d99-bc86-0ac967f38f33",
                "2c475c8b-f1ab-4277-aa87-09d9efe7610e",
                "2e438b01-f4fe-4ea3-9576-bcbf0ee1b946",
                "0ed88efb-c71d-4a22-82c0-383832b2edda",
                "d70b48b2-abbf-4dd9-a5f6-3ea68485353f",
                "57ce07e1-e5f8-4fc5-b9f6-ac7584e570cc",
                "316102ae-9ee6-438d-a416-43fcf091bcdb",
                "203cce98-fc22-43d9-af33-b7889e34a1c6",
                "a7c0ba0b-e7b3-430a-aa4c-6186a287c7db",
                "c03b2427-d0b6-4fec-9442-a7d8b230386b",
                "13b18619-51a7-4fd7-8461-855da071041a",
                "0d19ed30-0095-4e3e-94c7-c5437ba39bf7",
                "a729923e-f63d-479d-be92-7a326025eeb1"
              ],
              "instanceType": "StudyDesignPopulation",
              "description": "Target population defined by eligibility criteria"
            },
            "objectives": [
              {
                "id": "1b3e6651-fdfd-4315-951f-b26c5e2b0ee6",
                "name": "To demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the proportion of patients achievi...",
                "text": "To demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the proportion of patients achieving treatment success from insulin-induced hypoglycemia using a non-inferiority margin of 10%",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "d5a7689d-3654-40b6-b21f-9bdcda4c09af"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "e189cfea-e2c8-4e23-a049-374f200acd07",
                "name": "To compare the safety and tolerability of 3 mg LY900018 with 1 mg IMG",
                "text": "To compare the safety and tolerability of 3 mg LY900018 with 1 mg IMG",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "89491382-1911-439e-aa8a-8256d38057b2"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "33f59eae-2be7-4fec-948a-ddbe70f7b002",
                "name": "To characterize the PK profile of 3 mg LY900018 compared to 1 mg IMG",
                "text": "To characterize the PK profile of 3 mg LY900018 compared to 1 mg IMG",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "0055b37a-fc2d-4219-b136-691d79b9098b"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "c31e51d4-5fe2-4caf-8544-fe645ae1d7e8",
                "name": "To characterize the PD profile of 3 mg LY900018 compared to 1 mg IMG",
                "text": "To characterize the PD profile of 3 mg LY900018 compared to 1 mg IMG",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "ce95d84d-230b-4032-a50e-ac329f9b7d54"
                ],
                "instanceType": "Objective"
              }
            ],
            "endpoints": [
              {
                "id": "d5a7689d-3654-40b6-b21f-9bdcda4c09af",
                "name": "",
                "text": "The proportion of patients achieving treatment success defined as either an increase in PG to >70 mg/dL or an increase of >20 mg/dL from nadir within 30 minutes after administration of glucagon. The nadir is defined as the minimum PG value at the time of or within 10 minutes following glucagon administration.",
                "level": {
                  "id": "C98772",
                  "code": "C98772",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "89491382-1911-439e-aa8a-8256d38057b2",
                "name": "",
                "text": "SAE, TEAEs (including gastrointestinal, nasal, and non-nasal AEs), vital signs",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "0055b37a-fc2d-4219-b136-691d79b9098b",
                "name": "",
                "text": "PK parameters include AUC, Cmax, Tmax",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacokinetic"
              },
              {
                "id": "ce95d84d-230b-4032-a50e-ac329f9b7d54",
                "name": "",
                "text": "PD parameters include BGmax and Tmax",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacodynamic"
              }
            ],
            "scheduleTimelines": [
              {
                "id": "440a63ab-2474-42d6-8120-d7853e58a13f",
                "name": "Main Schedule Timeline",
                "mainTimeline": true,
                "instanceType": "ScheduleTimeline",
                "entryCondition": "Subject enrolled in study",
                "entryId": "4ee932de-68d5-4684-a50b-93e16ff0b596",
                "instances": [
                  {
                    "id": "4ee932de-68d5-4684-a50b-93e16ff0b596",
                    "activityIds": [
                      "73bab5af-d7e6-4010-a291-376910e61d58"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Informed Consent @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "5f90de6c-4d00-4187-9702-e60cc63481a7",
                    "activityIds": [
                      "75bed828-6780-40b9-95f0-792dab2c0b4e"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Randomization @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "0b90e5c4-e9e3-4b5a-bdbd-dbed83a54a1c",
                    "activityIds": [
                      "66177d07-1230-4ca5-8ab5-766071660173"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Admission to CRU @ Screening (Day -1)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "f0562e3b-4530-4797-9f97-41c3ddfbeade"
                  },
                  {
                    "id": "fb456fe1-558b-4765-ab92-3b5a178b6ed3",
                    "activityIds": [
                      "66177d07-1230-4ca5-8ab5-766071660173"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Admission to CRU @ Period 2 (Day -1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "cfa614f1-d587-46a2-87d6-5d3c846a20a1"
                  },
                  {
                    "id": "e4f78e87-e5fb-4e0f-b179-7d7313fff375",
                    "activityIds": [
                      "2cddb06b-1453-464d-b51c-b56678b88c53"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Discharge from CRU @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "607db304-2b33-4376-8fef-7ec560720104",
                    "activityIds": [
                      "2cddb06b-1453-464d-b51c-b56678b88c53"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Discharge from CRU @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "13807926-2b49-4f74-89b0-f2d7f4d20a44",
                    "activityIds": [
                      "a7a081ad-2fa2-40cf-af93-55a1d41189a1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Medical History @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "5b3abfd3-0240-4a0b-8854-078c04754648",
                    "activityIds": [
                      "390e57c5-59b0-43a2-872a-945ece6e892a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Pre-existing Conditions and Adverse Events @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "c34bc787-2901-43d8-94a3-43a4cdc197d7",
                    "activityIds": [
                      "390e57c5-59b0-43a2-872a-945ece6e892a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Pre-existing Conditions and Adverse Events @ Screening (Day -1)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "f0562e3b-4530-4797-9f97-41c3ddfbeade"
                  },
                  {
                    "id": "6b817560-b19a-48ab-aa21-f463e9ecc394",
                    "activityIds": [
                      "390e57c5-59b0-43a2-872a-945ece6e892a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Pre-existing Conditions and Adverse Events @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "d27e14c2-3632-4e78-b83d-5e7c1d352dc8",
                    "activityIds": [
                      "390e57c5-59b0-43a2-872a-945ece6e892a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Pre-existing Conditions and Adverse Events @ Wash out (3 to 14 days)",
                    "epochId": "3d64d9a8-6953-4f11-bdbf-6d65150c86b4",
                    "encounterId": "0bc9306c-3fbd-4ebb-a769-88024b1dd1de"
                  },
                  {
                    "id": "1b9d362e-e6ec-4a85-abb9-6df3955df827",
                    "activityIds": [
                      "390e57c5-59b0-43a2-872a-945ece6e892a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Pre-existing Conditions and Adverse Events @ Period 2 (Day -1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "cfa614f1-d587-46a2-87d6-5d3c846a20a1"
                  },
                  {
                    "id": "73d844ce-9a26-4a44-9a4a-e4ec4fc10a64",
                    "activityIds": [
                      "390e57c5-59b0-43a2-872a-945ece6e892a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Pre-existing Conditions and Adverse Events @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "fe1331dd-c727-4f86-a611-949971202c8d",
                    "activityIds": [
                      "390e57c5-59b0-43a2-872a-945ece6e892a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Pre-existing Conditions and Adverse Events @ Follow-up/ED (Within 28Â±2 d...",
                    "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                    "encounterId": "9587663e-fd95-44e7-906e-33067b44a3b8"
                  },
                  {
                    "id": "54d17242-0af3-47bf-8e53-5f83c2427caa",
                    "activityIds": [
                      "265ba280-1ab6-4393-a24a-a8ac56286c9a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical Exam @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "45a668d5-ef1f-4c03-9da8-9858b5aa0c79",
                    "activityIds": [
                      "265ba280-1ab6-4393-a24a-a8ac56286c9a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical Exam @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "4d6b1915-e5d8-4d4e-84c6-7e072f5b403f",
                    "activityIds": [
                      "265ba280-1ab6-4393-a24a-a8ac56286c9a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical Exam @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "67d6bfac-95c9-401f-9f9b-902ca17d45c9",
                    "activityIds": [
                      "265ba280-1ab6-4393-a24a-a8ac56286c9a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Physical Exam @ Follow-up/ED (Within 28Â±2 d...",
                    "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                    "encounterId": "9587663e-fd95-44e7-906e-33067b44a3b8"
                  },
                  {
                    "id": "a2f6b9d5-282a-4e41-af10-235399b4941d",
                    "activityIds": [
                      "e70937a3-9c88-465d-addd-97b58e9d1f03"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Height and Weight @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "fe49fd9e-ff98-4bd3-88b8-60be960e86b4",
                    "activityIds": [
                      "e70937a3-9c88-465d-addd-97b58e9d1f03"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Height and Weight @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "477297fe-b1ab-4f1f-bb6d-21497f1af4f4",
                    "activityIds": [
                      "e70937a3-9c88-465d-addd-97b58e9d1f03"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Height and Weight @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "16a54ce3-7bd0-4eb0-a0eb-b53cd07f6ecb",
                    "activityIds": [
                      "e70937a3-9c88-465d-addd-97b58e9d1f03"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Height and Weight @ Follow-up/ED (Within 28Â±2 d...",
                    "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                    "encounterId": "9587663e-fd95-44e7-906e-33067b44a3b8"
                  },
                  {
                    "id": "07bab881-617e-4821-9563-6854b316d12d",
                    "activityIds": [
                      "3bb4d631-b84f-4951-8665-a103e7d0a19a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Hypoglycemic Events @ Wash out (3 to 14 days)",
                    "epochId": "3d64d9a8-6953-4f11-bdbf-6d65150c86b4",
                    "encounterId": "0bc9306c-3fbd-4ebb-a769-88024b1dd1de"
                  },
                  {
                    "id": "3a1d3403-2a94-49fe-a7cc-e50683401c7f",
                    "activityIds": [
                      "3bb4d631-b84f-4951-8665-a103e7d0a19a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Hypoglycemic Events @ Follow-up/ED (Within 28Â±2 d...",
                    "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                    "encounterId": "9587663e-fd95-44e7-906e-33067b44a3b8"
                  },
                  {
                    "id": "189745ed-74e6-4c5e-97b7-6321d1a4f243",
                    "activityIds": [
                      "5a0b627c-61c3-4366-bb48-5d3e21620518"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Concomitant Medications @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "3aa9643a-2aa6-4be8-9625-07de72446633",
                    "activityIds": [
                      "5a0b627c-61c3-4366-bb48-5d3e21620518"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Concomitant Medications @ Screening (Day -1)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "f0562e3b-4530-4797-9f97-41c3ddfbeade"
                  },
                  {
                    "id": "c050b3b4-9801-41b8-ad55-3496e3d7f6d0",
                    "activityIds": [
                      "5a0b627c-61c3-4366-bb48-5d3e21620518"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Concomitant Medications @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "66dffcb2-3fec-467c-8d31-043b0abccf36",
                    "activityIds": [
                      "5a0b627c-61c3-4366-bb48-5d3e21620518"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Concomitant Medications @ Wash out (3 to 14 days)",
                    "epochId": "3d64d9a8-6953-4f11-bdbf-6d65150c86b4",
                    "encounterId": "0bc9306c-3fbd-4ebb-a769-88024b1dd1de"
                  },
                  {
                    "id": "f416d7e6-158f-49d5-9d79-25ae1f753187",
                    "activityIds": [
                      "5a0b627c-61c3-4366-bb48-5d3e21620518"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Concomitant Medications @ Period 2 (Day -1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "cfa614f1-d587-46a2-87d6-5d3c846a20a1"
                  },
                  {
                    "id": "05332ceb-5662-4bb7-b873-584dd9bb796b",
                    "activityIds": [
                      "5a0b627c-61c3-4366-bb48-5d3e21620518"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Concomitant Medications @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "3a6645f2-2f4f-447d-bbe6-565f8d81cf8f",
                    "activityIds": [
                      "5a0b627c-61c3-4366-bb48-5d3e21620518"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Collect Concomitant Medications @ Follow-up/ED (Within 28Â±2 d...",
                    "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                    "encounterId": "9587663e-fd95-44e7-906e-33067b44a3b8"
                  },
                  {
                    "id": "342e2be3-01a2-40f6-ac2a-80440f187610",
                    "activityIds": [
                      "a8012cc1-4ef5-4d6c-b88d-63a609bec36b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Meal @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "66b04291-9832-4d87-ba31-79c4b4f6ab62",
                    "activityIds": [
                      "a8012cc1-4ef5-4d6c-b88d-63a609bec36b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Meal @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "9d58afa1-6081-4e2e-a044-0177712cab58",
                    "activityIds": [
                      "832a24ed-5b9f-4365-b269-ba017d8cb757"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Insulin infusion to Induce Hypoglycemia @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "f1680ec2-6647-4fbd-8e35-5e44c63130cb",
                    "activityIds": [
                      "832a24ed-5b9f-4365-b269-ba017d8cb757"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Insulin infusion to Induce Hypoglycemia @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "65679b76-1d9c-41b2-9638-d4c1c84946dd",
                    "activityIds": [
                      "18ad9d91-bc9e-4067-a67a-4aa9d2fdd5f9"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Bedside PG Monitoring for Safety @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "fca01c90-840c-4228-9558-470a00e2bf3a",
                    "activityIds": [
                      "18ad9d91-bc9e-4067-a67a-4aa9d2fdd5f9"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Bedside PG Monitoring for Safety @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "1fccb330-ce8f-4e3e-a1c7-0bdd427c0dd0",
                    "activityIds": [
                      "104bb020-ab81-47b4-886c-f079868bb92a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Study Treatment Administration @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "0395a24c-a877-4ebe-83e5-d310964eb98d",
                    "activityIds": [
                      "104bb020-ab81-47b4-886c-f079868bb92a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Study Treatment Administration @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "bb912b0d-e1a9-4b8b-bffd-b9066c5cb725",
                    "activityIds": [
                      "c064b2bc-901d-485e-bdc4-c5bac01aed7c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Injection-Site Assessment @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "f3b05524-6a80-42a4-b2ec-8ac00c901c16",
                    "activityIds": [
                      "c064b2bc-901d-485e-bdc4-c5bac01aed7c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Injection-Site Assessment @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "a7490f83-aa33-4771-be05-c762c58e997b",
                    "activityIds": [
                      "7b2c541b-a54c-459f-ba5b-836241df1d60"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Nasal Inspection @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "18c08ccb-5627-4bd0-885c-91b6f0811304",
                    "activityIds": [
                      "7b2c541b-a54c-459f-ba5b-836241df1d60"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Nasal Inspection @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "d093f924-bae3-4bd7-97db-9eb112a7aa8c",
                    "activityIds": [
                      "e111c2d7-73d1-4739-acd7-8c774ea24b98"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Vital Signs (Supine Blood Pressure, Pulse Rate,... @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "94c32ce2-d467-4bef-b211-ea8472af9c66",
                    "activityIds": [
                      "e111c2d7-73d1-4739-acd7-8c774ea24b98"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Vital Signs (Supine Blood Pressure, Pulse Rate,... @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "16a080f4-2b20-4bef-b504-d103a0808469",
                    "activityIds": [
                      "e111c2d7-73d1-4739-acd7-8c774ea24b98"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Vital Signs (Supine Blood Pressure, Pulse Rate,... @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "18d9d664-4055-4870-aa73-1eb20d9bce90",
                    "activityIds": [
                      "e111c2d7-73d1-4739-acd7-8c774ea24b98"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Vital Signs (Supine Blood Pressure, Pulse Rate,... @ Follow-up/ED (Within 28Â±2 d...",
                    "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                    "encounterId": "9587663e-fd95-44e7-906e-33067b44a3b8"
                  },
                  {
                    "id": "baa8481a-2743-4ae2-a083-ad14318b7c86",
                    "activityIds": [
                      "986c562e-c944-465d-bc42-2ed8bcbd1d60"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Single 12-lead ECG (Local) @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "71fccf92-bbc7-4d6b-826f-344969695c61",
                    "activityIds": [
                      "986c562e-c944-465d-bc42-2ed8bcbd1d60"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Single 12-lead ECG (Local) @ Follow-up/ED (Within 28Â±2 d...",
                    "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                    "encounterId": "9587663e-fd95-44e7-906e-33067b44a3b8"
                  },
                  {
                    "id": "607b62da-ce82-4ec7-9b80-ce07ed28f6e6",
                    "activityIds": [
                      "1da547ed-1d71-4fb7-9efb-53ea10f64d58"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Triplicate 12-lead ECG (Central) @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "107b943e-b989-4651-9b74-d22489c943ae",
                    "activityIds": [
                      "1da547ed-1d71-4fb7-9efb-53ea10f64d58"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Triplicate 12-lead ECG (Central) @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "865f3609-f821-4070-8a9b-a4d9cb288823",
                    "activityIds": [
                      "43fed1de-4ec0-4c83-95c6-00e778f42a15"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Clinical Serology Tests @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "7ec744b9-e887-4ef8-87f9-2c7a03289425",
                    "activityIds": [
                      "bdbd40f7-1ec7-4662-b995-1e6836e177ba"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Clinical Lab Tests (Hematology, Clinical Chemis... @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "c35dd138-2877-4807-a45e-5d6599127b2b",
                    "activityIds": [
                      "bdbd40f7-1ec7-4662-b995-1e6836e177ba"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Clinical Lab Tests (Hematology, Clinical Chemis... @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "c378dfc1-2f94-405d-84f1-7b16c1f12881",
                    "activityIds": [
                      "bdbd40f7-1ec7-4662-b995-1e6836e177ba"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Clinical Lab Tests (Hematology, Clinical Chemis... @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "c40e8c9f-a442-4aa3-a2f4-9e0efea6d2e4",
                    "activityIds": [
                      "bdbd40f7-1ec7-4662-b995-1e6836e177ba"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Clinical Lab Tests (Hematology, Clinical Chemis... @ Follow-up/ED (Within 28Â±2 d...",
                    "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                    "encounterId": "9587663e-fd95-44e7-906e-33067b44a3b8"
                  },
                  {
                    "id": "b25b85ab-f009-43d4-86d5-756411a730e7",
                    "activityIds": [
                      "04a6ac1c-0537-4d96-8125-ab9ed2aa490e"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "HbA1c @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "4cdf5904-0c01-4f0b-9d10-b346a003f298",
                    "activityIds": [
                      "04a6ac1c-0537-4d96-8125-ab9ed2aa490e"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "HbA1c @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "2be16a1d-cf50-4612-97aa-e24ada5e014f",
                    "activityIds": [
                      "e58e3523-ea5a-4ce5-a5fb-19583e88dd55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Pregnancy Test (Female patients of childbearing... @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "c2661e30-abf9-4a07-8a5d-b59a25c1b922",
                    "activityIds": [
                      "e58e3523-ea5a-4ce5-a5fb-19583e88dd55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Pregnancy Test (Female patients of childbearing... @ Screening (Day -1)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "f0562e3b-4530-4797-9f97-41c3ddfbeade"
                  },
                  {
                    "id": "8bffc346-3af3-49ed-99f9-cd2735b38097",
                    "activityIds": [
                      "e58e3523-ea5a-4ce5-a5fb-19583e88dd55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Pregnancy Test (Female patients of childbearing... @ Period 2 (Day -1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "cfa614f1-d587-46a2-87d6-5d3c846a20a1"
                  },
                  {
                    "id": "dc62deae-a905-46db-8fc0-8e51639ceb99",
                    "activityIds": [
                      "e58e3523-ea5a-4ce5-a5fb-19583e88dd55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Pregnancy Test (Female patients of childbearing... @ Follow-up/ED (Within 28Â±2 d...",
                    "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                    "encounterId": "9587663e-fd95-44e7-906e-33067b44a3b8"
                  },
                  {
                    "id": "a2952f96-61e6-46dd-994f-3d2b612f74cf",
                    "activityIds": [
                      "7c8df6c7-4fd5-4e33-9658-18dd606e5431"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "FSH (Female patients only) @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "bb2465c2-053d-4e6d-8cde-0397570ecc3a",
                    "activityIds": [
                      "8b41e22a-7035-4254-a06a-3d6af6beebbc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Ethanol Testing @ Screening (Day -1)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "f0562e3b-4530-4797-9f97-41c3ddfbeade"
                  },
                  {
                    "id": "31722c97-e5b7-482d-8634-60e976d9cc5e",
                    "activityIds": [
                      "5f53b92f-257c-40ff-9734-d5205d47f3d5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Urine Drug Screen @ Screening (Day -1)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "f0562e3b-4530-4797-9f97-41c3ddfbeade"
                  },
                  {
                    "id": "9118a146-5b53-4fe7-9d03-e1359f726c0e",
                    "activityIds": [
                      "d538477e-8a88-467a-893f-79b9e8495e53"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "PK (Glucagon) @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "ef007b77-5a0b-4f08-bd83-f240dad9fc47",
                    "activityIds": [
                      "d538477e-8a88-467a-893f-79b9e8495e53"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "PK (Glucagon) @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "951bafec-3232-4482-97b1-0cea74bd8775",
                    "activityIds": [
                      "d538477e-8a88-467a-893f-79b9e8495e53"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "PK (Glucagon) @ Follow-up/ED (Within 28Â±2 d...",
                    "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                    "encounterId": "9587663e-fd95-44e7-906e-33067b44a3b8"
                  },
                  {
                    "id": "f0817f91-5b34-4244-9ba6-7f9f5fd68a6d",
                    "activityIds": [
                      "d538477e-8a88-467a-893f-79b9e8495e53"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "PK (Glucagon) @ Additional Follow-up for TE...",
                    "epochId": "7d335965-fac7-4587-81d4-8e1fe13187dd",
                    "encounterId": "c104f0bc-6a42-4cc0-8d4a-6e11618d68b4"
                  },
                  {
                    "id": "2ff5cdbb-6ba2-40ae-bb44-ba098513f664",
                    "activityIds": [
                      "57539182-29aa-4a00-a82e-92dae8ed7575"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Plasma Glucose for PD @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "f9240cd6-99a5-4d4c-b39a-d23048a16fd9",
                    "activityIds": [
                      "57539182-29aa-4a00-a82e-92dae8ed7575"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Plasma Glucose for PD @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "3602bc4b-6e03-49ba-8ac5-9e1869934a9c",
                    "activityIds": [
                      "dc8b5f95-7ad3-4263-951c-3d3dd82674c9"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Genetic Sample (Stored) @ Screening (Day -1)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "f0562e3b-4530-4797-9f97-41c3ddfbeade"
                  },
                  {
                    "id": "3b1fe0ec-1225-4fdb-9bff-763c9df5ddab",
                    "activityIds": [
                      "5638a44a-dc63-46b4-b00b-db885c8caa67"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Anti-glucagon Antibodies @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "df19b8f6-73a3-4a8d-8696-4696ef3c2c95",
                    "activityIds": [
                      "5638a44a-dc63-46b4-b00b-db885c8caa67"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Anti-glucagon Antibodies @ Follow-up/ED (Within 28Â±2 d...",
                    "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                    "encounterId": "9587663e-fd95-44e7-906e-33067b44a3b8"
                  },
                  {
                    "id": "71f09ff5-c474-4d64-9383-2a7257e4819f",
                    "activityIds": [
                      "5638a44a-dc63-46b4-b00b-db885c8caa67"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Anti-glucagon Antibodies @ Additional Follow-up for TE...",
                    "epochId": "7d335965-fac7-4587-81d4-8e1fe13187dd",
                    "encounterId": "c104f0bc-6a42-4cc0-8d4a-6e11618d68b4"
                  },
                  {
                    "id": "437aa8ff-2810-4489-94b1-1b16a057dbe0",
                    "activityIds": [
                      "6b9615b3-0ad8-419d-bcdb-d7ef3b79a99f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Clarke Hypoglycemia Awareness Survey @ Screening (Days -28 to -2)",
                    "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                    "encounterId": "bb20271b-e33a-4b33-930d-c5dc8a3a6048"
                  },
                  {
                    "id": "27b239ba-f430-4bad-b3ef-cd798435ea09",
                    "activityIds": [
                      "59280ca4-ed25-421b-9554-9a2b833b8b20"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Nasal and Non-nasal Score Questionnaire @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "729ae24f-bc7f-4487-a0a6-49a163ad3513",
                    "activityIds": [
                      "59280ca4-ed25-421b-9554-9a2b833b8b20"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Nasal and Non-nasal Score Questionnaire @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  },
                  {
                    "id": "f5f6d2ee-36fd-40c9-a9f8-b30474369d4d",
                    "activityIds": [
                      "f7e38bb5-dfb0-41eb-b9ae-e4751ede0e38"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Edinburgh Hypoglycemia Scale: Experimental Hypo... @ Period 1 (Day 1)",
                    "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                    "encounterId": "7f533543-0f97-4b1a-b91a-6d0203279fb9"
                  },
                  {
                    "id": "79612d7f-da2c-47d7-96bd-84e488a62a63",
                    "activityIds": [
                      "f7e38bb5-dfb0-41eb-b9ae-e4751ede0e38"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "Edinburgh Hypoglycemia Scale: Experimental Hypo... @ Period 2 (Day 1)",
                    "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                    "encounterId": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e"
                  }
                ]
              }
            ],
            "encounters": [
              {
                "id": "bb20271b-e33a-4b33-930d-c5dc8a3a6048",
                "name": "Screening (Days -28 to -2)",
                "instanceType": "Encounter",
                "type": {
                  "id": "f05e8d70-bef0-498b-ad86-b9183f95adef",
                  "code": "C48262",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening",
                  "instanceType": "Code"
                },
                "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2"
              },
              {
                "id": "f0562e3b-4530-4797-9f97-41c3ddfbeade",
                "name": "Screening (Day -1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "4cdeeb9c-9c30-4010-bdae-ac630a709596",
                  "code": "C48262",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening",
                  "instanceType": "Code"
                },
                "epochId": "764a1f6f-274b-43f4-9df0-89f0b4545dd2"
              },
              {
                "id": "7f533543-0f97-4b1a-b91a-6d0203279fb9",
                "name": "Period 1 (Day 1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "69d2d7b0-3ad6-492f-a9cd-4e11d7b2c32f",
                  "code": "C82517",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Baseline",
                  "instanceType": "Code"
                },
                "epochId": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863"
              },
              {
                "id": "0bc9306c-3fbd-4ebb-a769-88024b1dd1de",
                "name": "Wash out (3 to 14 days)",
                "instanceType": "Encounter",
                "type": {
                  "id": "01a634d6-8e18-4ae5-b4b9-9313842e0a9b",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "3d64d9a8-6953-4f11-bdbf-6d65150c86b4"
              },
              {
                "id": "cfa614f1-d587-46a2-87d6-5d3c846a20a1",
                "name": "Period 2 (Day -1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "c9fff9c8-aee3-4e0a-a403-8983252ef977",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86"
              },
              {
                "id": "7f4d766c-f3ee-4be2-a4fa-4fa12f83005e",
                "name": "Period 2 (Day 1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "484c3517-e9b3-4c49-9424-608d5e3c00d0",
                  "code": "C82517",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Baseline",
                  "instanceType": "Code"
                },
                "epochId": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86"
              },
              {
                "id": "9587663e-fd95-44e7-906e-33067b44a3b8",
                "name": "Follow-up/ED (Within 28Â±2 days)",
                "instanceType": "Encounter",
                "type": {
                  "id": "f3321f40-cf69-481b-8aa3-c181fe9601af",
                  "code": "C99158",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up",
                  "instanceType": "Code"
                },
                "epochId": "b08e6c4d-5987-473d-9447-3e7a20abfefb"
              },
              {
                "id": "c104f0bc-6a42-4cc0-8d4a-6e11618d68b4",
                "name": "Additional Follow-up for TE ADA",
                "instanceType": "Encounter",
                "type": {
                  "id": "37d30a93-4b6f-4c0b-98dc-4cf5f56d5b68",
                  "code": "C99158",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up",
                  "instanceType": "Code"
                },
                "epochId": "7d335965-fac7-4587-81d4-8e1fe13187dd"
              }
            ],
            "activities": [
              {
                "id": "2be1194d-24a7-4a31-81f9-f676f614d449",
                "name": "Clinical Assessments",
                "instanceType": "Activity",
                "childIds": [
                  "73bab5af-d7e6-4010-a291-376910e61d58",
                  "75bed828-6780-40b9-95f0-792dab2c0b4e",
                  "66177d07-1230-4ca5-8ab5-766071660173",
                  "2cddb06b-1453-464d-b51c-b56678b88c53",
                  "a7a081ad-2fa2-40cf-af93-55a1d41189a1",
                  "390e57c5-59b0-43a2-872a-945ece6e892a",
                  "265ba280-1ab6-4393-a24a-a8ac56286c9a",
                  "e70937a3-9c88-465d-addd-97b58e9d1f03",
                  "3bb4d631-b84f-4951-8665-a103e7d0a19a",
                  "5a0b627c-61c3-4366-bb48-5d3e21620518",
                  "a8012cc1-4ef5-4d6c-b88d-63a609bec36b",
                  "832a24ed-5b9f-4365-b269-ba017d8cb757",
                  "18ad9d91-bc9e-4067-a67a-4aa9d2fdd5f9",
                  "104bb020-ab81-47b4-886c-f079868bb92a",
                  "c064b2bc-901d-485e-bdc4-c5bac01aed7c",
                  "7b2c541b-a54c-459f-ba5b-836241df1d60",
                  "e111c2d7-73d1-4739-acd7-8c774ea24b98",
                  "986c562e-c944-465d-bc42-2ed8bcbd1d60",
                  "1da547ed-1d71-4fb7-9efb-53ea10f64d58"
                ],
                "notes": [
                  {
                    "id": "de615279-d452-454c-92d3-d405e35280fc",
                    "text": "Study Population\nEligibility of patients for the study will be based on the results of screening medical history, \nphysical examination, vital signs, clinical laboratory tests, and ECG",
                    "instanceType": "Note"
                  },
                  {
                    "id": "9721e0da-7285-4b7a-9e1b-17fe75a45125",
                    "text": "Study Assessments and Procedures\nSection",
                    "instanceType": "Note"
                  },
                  {
                    "id": "cea9ef89-985b-4a83-b517-1d358b1ba1c0",
                    "text": "Efficacy Assessments\nPlasma glucose levels will be measured as described in Section",
                    "instanceType": "Note"
                  },
                  {
                    "id": "8a3ab790-de7d-4220-bc7a-5a77fc725298",
                    "text": "Primary Efficacy Assessments\nThe primary efficacy measure is the proportion of patients achieving treatment success, defined \nas either an increase in PG to >",
                    "instanceType": "Note"
                  },
                  {
                    "id": "ba00b184-df5f-4fd8-b45d-3647b0c9e3a7",
                    "text": "Secondary Efficacy Assessments\nSecondary efficacy measures will be determined from the pharmacodynamic",
                    "instanceType": "Note"
                  },
                  {
                    "id": "d5f8f2be-5e0e-45c6-8748-8e35e9af0b60",
                    "text": "Exploratory Efficacy Assessments\nSubjective hypoglycemia symptoms will be assessed using a self-reported assessment tool",
                    "instanceType": "Note"
                  },
                  {
                    "id": "797bebd4-e756-4517-ac75-e046bd6ee85f",
                    "text": "Insulin-induced Hypoglycemia\nA study investigator, or qualified designee, must be present at the bedside for clinical \nassessments of the patient during the insulin infusion and for the",
                    "instanceType": "Note"
                  },
                  {
                    "id": "bffd8149-84d8-405b-a0fd-253e4ff71114",
                    "text": "Immunogenicity Assessments\nAt the visits and times specified in the Schedule of Activities",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "0acb5dbd-f69d-42b4-8403-e132fc0db77f",
                "name": "Laboratory Tests",
                "instanceType": "Activity",
                "childIds": [
                  "43fed1de-4ec0-4c83-95c6-00e778f42a15",
                  "bdbd40f7-1ec7-4662-b995-1e6836e177ba",
                  "04a6ac1c-0537-4d96-8125-ab9ed2aa490e",
                  "e58e3523-ea5a-4ce5-a5fb-19583e88dd55",
                  "7c8df6c7-4fd5-4e33-9658-18dd606e5431",
                  "8b41e22a-7035-4254-a06a-3d6af6beebbc",
                  "5f53b92f-257c-40ff-9734-d5205d47f3d5",
                  "d538477e-8a88-467a-893f-79b9e8495e53",
                  "57539182-29aa-4a00-a82e-92dae8ed7575",
                  "dc8b5f95-7ad3-4263-951c-3d3dd82674c9",
                  "5638a44a-dc63-46b4-b00b-db885c8caa67"
                ],
                "extensionAttributes": [
                  {
                    "id": "19d60650-7c3d-4778-86cf-683c9590bf33",
                    "url": "https://protocol2usdm.io/extensions/x-executionModel-executionType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "{\"activityId\": \"Laboratory Tests\", \"executionType\": \"Window\", \"rationale\": \"WINDOW signals: 1; SINGLE signals: 1\"}"
                  }
                ],
                "notes": [
                  {
                    "id": "5198f40b-2b61-45ca-8cf4-7249779c7de5",
                    "text": "Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \nwill be destroyed within",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e68c2382-a062-4d0c-8d09-a048b7433a6a",
                    "text": "Certain samples may be \nretained for a longer period, if necessary, to comply with applicable laws, regulations, or \nlaboratory certification standards",
                    "instanceType": "Note"
                  },
                  {
                    "id": "bdae1caa-8d50-4410-b5c7-3b26d7874ad4",
                    "text": "The central ECG laboratory will perform a basic quality control check",
                    "instanceType": "Note"
                  },
                  {
                    "id": "4f933aab-44bc-446f-8dcf-4552d3811ac6",
                    "text": "At a future time, the stored \nECG data may be overread at the central ECG laboratory for further evaluation of machine-read \nmeasurements or to meet regulatory requirements",
                    "instanceType": "Note"
                  },
                  {
                    "id": "fe4e5d13-e3ee-42d8-b5f6-f10cb84a9e46",
                    "text": "Study Population\nEligibility of patients for the study will be based on the results of screening medical history, \nphysical examination, vital signs, clinical laboratory tests, and ECG",
                    "instanceType": "Note"
                  },
                  {
                    "id": "a265be91-cc77-4e09-8cbc-d2b652291d6b",
                    "text": "Laboratory Tests\nFor each patient, laboratory tests detailed in Appendix",
                    "instanceType": "Note"
                  },
                  {
                    "id": "517f8e9e-a634-455d-a802-881e83f3e7f5",
                    "text": "Bioanalysis\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facility \ndesignated by the sponsor",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "ab34b46e-cff3-4917-ba94-5cc4870be5b5",
                "name": "Health Outcome Instruments",
                "instanceType": "Activity",
                "childIds": [
                  "6b9615b3-0ad8-419d-bcdb-d7ef3b79a99f",
                  "59280ca4-ed25-421b-9554-9a2b833b8b20",
                  "f7e38bb5-dfb0-41eb-b9ae-e4751ede0e38"
                ]
              },
              {
                "id": "73bab5af-d7e6-4010-a291-376910e61d58",
                "name": "Informed Consent",
                "instanceType": "Activity",
                "description": "Informed Consent"
              },
              {
                "id": "75bed828-6780-40b9-95f0-792dab2c0b4e",
                "name": "Randomization",
                "instanceType": "Activity",
                "description": "Randomization"
              },
              {
                "id": "66177d07-1230-4ca5-8ab5-766071660173",
                "name": "Admission to CRU",
                "instanceType": "Activity",
                "description": "Admission can be rescheduled if PG level is not 90 to 250 mg/dL on Day 1."
              },
              {
                "id": "2cddb06b-1453-464d-b51c-b56678b88c53",
                "name": "Discharge from CRU",
                "instanceType": "Activity",
                "description": "Patient may be discharged 6 hours after glucagon administration. A patient may remain inpatient at the CRU at the discretion of the investigator.",
                "notes": [
                  {
                    "id": "458be938-508c-4d07-8ca9-fb1574788c23",
                    "text": "Secondary Efficacy Assessments\nSecondary efficacy measures will be determined from the pharmacodynamic",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "a7a081ad-2fa2-40cf-af93-55a1d41189a1",
                "name": "Medical History",
                "instanceType": "Activity",
                "description": "Medical History",
                "notes": [
                  {
                    "id": "63d9c842-7f38-48d7-8cde-f4b5f198f083",
                    "text": "Study Population\nEligibility of patients for the study will be based on the results of screening medical history, \nphysical examination, vital signs, clinical laboratory tests, and ECG",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "390e57c5-59b0-43a2-872a-945ece6e892a",
                "name": "Collect Pre-existing Conditions and Adverse Events",
                "instanceType": "Activity",
                "description": "Collect Pre-existing Conditions and Adverse Events",
                "notes": [
                  {
                    "id": "2e6333cd-9147-491d-a06b-27cfa66ea5b5",
                    "text": "a\nSamples for immunogenicity, should be collected every",
                    "instanceType": "Note"
                  },
                  {
                    "id": "58c3afea-586e-4671-a310-bb1dbb1d9401",
                    "text": "Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \nwill be destroyed within",
                    "instanceType": "Note"
                  },
                  {
                    "id": "04116c50-6019-4ebb-ba66-b73686e29b3c",
                    "text": "Single ECGs will be collected and stored locally at the investigatorâs site",
                    "instanceType": "Note"
                  },
                  {
                    "id": "7283b57a-8dd4-4fd6-b9b2-f611f1d5bbbe",
                    "text": "To interpret the results of \nimmunogenicity, a venous blood sample may be collected at the same time points to determine \nthe concentrations of glucagon",
                    "instanceType": "Note"
                  },
                  {
                    "id": "65f200a8-a3d7-43bc-92c3-0478aa29f450",
                    "text": "A PK sample may be collected at these \nsame time points",
                    "instanceType": "Note"
                  },
                  {
                    "id": "9bc4684c-2cda-4db7-9999-32dddd4c40fe",
                    "text": "A PK \nsample may be collected at the follow-up immunogenicity assessment",
                    "instanceType": "Note"
                  },
                  {
                    "id": "44d4c7e7-6ed1-4033-957d-264a04063f97",
                    "text": "Electrocardiograms\nFor each patient, single and triplicate ECGs should be collected according to the Schedule of \nActivities",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "265ba280-1ab6-4393-a24a-a8ac56286c9a",
                "name": "Physical Exam",
                "instanceType": "Activity",
                "description": "After screening, medical assessment only performed to include medical review and targeted examination, as appropriate.",
                "definedProcedures": [
                  {
                    "id": "ad06924a-9c2d-4360-95ce-b4d25a973039",
                    "name": "Physical Examination",
                    "procedureType": "Assessment",
                    "code": {
                      "id": "d1f4c97b-c78f-424d-86fb-c8e9bf76eafb",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Physical Examination",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Physical Exam",
                    "description": "Includes measurement of height and weight."
                  }
                ],
                "notes": [
                  {
                    "id": "13c513f4-77b8-48c1-b1e6-7f43d8b872c2",
                    "text": "The nature of any conditions present at the time of the physical examination and any preexisting \nconditions will be documented",
                    "instanceType": "Note"
                  },
                  {
                    "id": "882236c8-546d-443d-ab00-3bbcac669550",
                    "text": "Study Population\nEligibility of patients for the study will be based on the results of screening medical history, \nphysical examination, vital signs, clinical laboratory tests, and ECG",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "e70937a3-9c88-465d-addd-97b58e9d1f03",
                "name": "Height and Weight",
                "instanceType": "Activity",
                "description": "Height is at screening only. Weight on Day 1 will be collected before the start of the procedure to induce hypoglycemia."
              },
              {
                "id": "3bb4d631-b84f-4951-8665-a103e7d0a19a",
                "name": "Collect Hypoglycemic Events",
                "instanceType": "Activity",
                "description": "Refer to Section 9.5.5.1."
              },
              {
                "id": "5a0b627c-61c3-4366-bb48-5d3e21620518",
                "name": "Collect Concomitant Medications",
                "instanceType": "Activity",
                "description": "Review patientsâ insulin regimens to confirm acceptability to undergo the procedure to induce hypoglycemia."
              },
              {
                "id": "a8012cc1-4ef5-4d6c-b88d-63a609bec36b",
                "name": "Meal",
                "instanceType": "Activity",
                "description": "After completion of all PK sampling, patients will be provided a carbohydrate-rich meal. The investigator will ensure the patientâs PG is stable. A prandial insulin dose will be administered if needed."
              },
              {
                "id": "832a24ed-5b9f-4365-b269-ba017d8cb757",
                "name": "Insulin infusion to Induce Hypoglycemia",
                "instanceType": "Activity",
                "description": "Procedures in Period 2 will occur at approximately the same time as those in Period 1. Insulin infusion is stopped once bedside PG is <60 mg/dL.",
                "definedProcedures": [
                  {
                    "id": "c09c952a-af66-46e8-9f56-13c49e0b9bc5",
                    "name": "Insulin Infusion",
                    "procedureType": "Therapeutic Procedure",
                    "code": {
                      "id": "f1f9cec4-e668-471c-ac09-c9360d9ce846",
                      "code": "96365",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "2024-09-27",
                      "decode": "Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Insulin Infusion",
                    "description": "Intravenous (IV) insulin infusion to induce hypoglycemia."
                  }
                ],
                "notes": [
                  {
                    "id": "985071e1-a000-4cf5-9dae-dc429bf9c00a",
                    "text": "multiple daily injection of long-acting insulin analog",
                    "instanceType": "Note"
                  },
                  {
                    "id": "4db5d30f-e60f-49a7-8146-0861b31bca94",
                    "text": "Predose time point will be\nbetween insulin infusion \nstop and study treatment",
                    "instanceType": "Note"
                  },
                  {
                    "id": "50913acc-ac79-4e50-96bc-f917c438cde3",
                    "text": "Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \nposture-induced symptoms",
                    "instanceType": "Note"
                  },
                  {
                    "id": "1e4238f9-6e13-410b-8cd3-8642993d94fa",
                    "text": "Exploratory Efficacy Assessments\nSubjective hypoglycemia symptoms will be assessed using a self-reported assessment tool",
                    "instanceType": "Note"
                  },
                  {
                    "id": "c30fc34c-b437-4c6c-8218-60b1782e8b6c",
                    "text": "Insulin-induced Hypoglycemia\nA study investigator, or qualified designee, must be present at the bedside for clinical \nassessments of the patient during the insulin infusion and for the",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "18ad9d91-bc9e-4067-a67a-4aa9d2fdd5f9",
                "name": "Bedside PG Monitoring for Safety",
                "instanceType": "Activity",
                "description": "Samples will be collected during the hypoglycemia induction procedure and post study treatment (up to 120 mins). Bedside PG monitoring will be conducted no more than 10 minutes apart while bedside PG is â¥90 mg/dL and no more than 5 minutes apart when bedside PG is <90 mg/dL.",
                "notes": [
                  {
                    "id": "2957edbb-2e5b-4233-9d23-39de954008d2",
                    "text": "Insulin-induced Hypoglycemia\nA study investigator, or qualified designee, must be present at the bedside for clinical \nassessments of the patient during the insulin infusion and for the",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "104bb020-ab81-47b4-886c-f079868bb92a",
                "name": "Study Treatment Administration",
                "instanceType": "Activity",
                "description": "Once bedside PG reaches <60 mg/dL, the insulin infusion is stopped and approximately 5 minutes later study drug is administered. Indicates Time = 0 min.",
                "notes": [
                  {
                    "id": "7824b638-6da0-455f-94fd-ae6541681cb7",
                    "text": "women of childbearing potential participating must test negative for \npregnancy prior to initiation of treatment as indicated by a negative serum \npregnancy test at the screening visit followed by a negative urine \npregnancy test within",
                    "instanceType": "Note"
                  },
                  {
                    "id": "0c077932-a6a2-423f-a339-094fa0527105",
                    "text": "Predose time point will be\nbetween insulin infusion \nstop and study treatment",
                    "instanceType": "Note"
                  },
                  {
                    "id": "8cf57dd4-fc76-4cbd-93b2-649210bca048",
                    "text": "Treatment-emergent antidrug antibodies",
                    "instanceType": "Note"
                  },
                  {
                    "id": "44fd851f-d632-4923-9b2e-85542cecd801",
                    "text": "male patients: agree to use an effective method of contraception for the \nduration of the study and for",
                    "instanceType": "Note"
                  },
                  {
                    "id": "869685bb-f455-47ca-8549-36ab90403242",
                    "text": "Study Population\nEligibility of patients for the study will be based on the results of screening medical history, \nphysical examination, vital signs, clinical laboratory tests, and ECG",
                    "instanceType": "Note"
                  },
                  {
                    "id": "51034cc2-0ff3-4c33-b73e-dbc491b6ab71",
                    "text": "Inclusion Criteria\nPatients are eligible for inclusion in the study only if they meet all of the following criteria at \nscreening and/or enrollment:",
                    "instanceType": "Note"
                  },
                  {
                    "id": "469841e7-6137-4574-b12e-f1dca5b5f17e",
                    "text": "Study Assessments and Procedures\nSection",
                    "instanceType": "Note"
                  },
                  {
                    "id": "f6847aec-bdb7-42ec-9561-1643e417e598",
                    "text": "Primary Efficacy Assessments\nThe primary efficacy measure is the proportion of patients achieving treatment success, defined \nas either an increase in PG to >",
                    "instanceType": "Note"
                  },
                  {
                    "id": "58f96562-3e75-4fb1-8927-a8c4444217f2",
                    "text": "Insulin-induced Hypoglycemia\nA study investigator, or qualified designee, must be present at the bedside for clinical \nassessments of the patient during the insulin infusion and for the",
                    "instanceType": "Note"
                  },
                  {
                    "id": "09cb12ff-e3b8-4355-b0e8-d4cd6715d0c0",
                    "text": "Treatment of Overdose\nFor the purposes of this study, an overdose of LY",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e5c732c8-f975-4b34-8f86-3757476f76a5",
                    "text": "If the \nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \ndefinition of treatment emergent, then, at the discretion of the sponsor, patients should be called \nback to the site for follow-up immunogenicity assessment",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "c064b2bc-901d-485e-bdc4-c5bac01aed7c",
                "name": "Injection-Site Assessment",
                "instanceType": "Activity",
                "description": "Injection-site assessment for IMG only.",
                "definedProcedures": [
                  {
                    "id": "a1afa437-0ae4-4264-9249-eb320d6c3ff8",
                    "name": "Injection-Site Assessment",
                    "procedureType": "Assessment",
                    "code": {
                      "id": "88cbde06-3844-46ea-9a32-0cca2919fe7b",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Injection-Site Assessment",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Injection-Site Assessment",
                    "description": "Assessment of the injection site for patients receiving intramuscular glucagon (IMG)."
                  }
                ],
                "notes": [
                  {
                    "id": "3c31dd98-c171-4f9c-b88d-436b2047953b",
                    "text": "A PK \nsample may be collected at the follow-up immunogenicity assessment",
                    "instanceType": "Note"
                  },
                  {
                    "id": "cfb3d947-41eb-4d60-b698-03e9b36e85c8",
                    "text": "Every attempt should be made to contact \npatients for the follow-up immunogenicity assessment; however, if patients are unwilling or \nunable to return for the visit, this is not considered a protocol violation",
                    "instanceType": "Note"
                  },
                  {
                    "id": "311707c0-5d79-4448-bcd5-a9c761d6caaa",
                    "text": "Study Assessments and Procedures\nSection",
                    "instanceType": "Note"
                  },
                  {
                    "id": "7b5ba29c-1518-4e73-9718-a7414cde25e9",
                    "text": "Efficacy Assessments\nPlasma glucose levels will be measured as described in Section",
                    "instanceType": "Note"
                  },
                  {
                    "id": "ddd9175d-5abe-4311-8dfc-5e52ee6ae0fd",
                    "text": "Primary Efficacy Assessments\nThe primary efficacy measure is the proportion of patients achieving treatment success, defined \nas either an increase in PG to >",
                    "instanceType": "Note"
                  },
                  {
                    "id": "3db13f8c-a48a-41b5-bea0-bcd70dd9d27d",
                    "text": "Secondary Efficacy Assessments\nSecondary efficacy measures will be determined from the pharmacodynamic",
                    "instanceType": "Note"
                  },
                  {
                    "id": "cba08349-c6c8-4079-9af0-f167f4b3dae3",
                    "text": "Exploratory Efficacy Assessments\nSubjective hypoglycemia symptoms will be assessed using a self-reported assessment tool",
                    "instanceType": "Note"
                  },
                  {
                    "id": "ac3ca85a-87b8-49c3-abd1-c734e8df3654",
                    "text": "Insulin-induced Hypoglycemia\nA study investigator, or qualified designee, must be present at the bedside for clinical \nassessments of the patient during the insulin infusion and for the",
                    "instanceType": "Note"
                  },
                  {
                    "id": "053ffb0e-6c56-4c0c-a35f-c753ad897a94",
                    "text": "Immunogenicity Assessments\nAt the visits and times specified in the Schedule of Activities",
                    "instanceType": "Note"
                  },
                  {
                    "id": "951bbcbe-8bf4-4ffe-ac4e-8ac90dce697e",
                    "text": "If the \nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \ndefinition of treatment emergent, then, at the discretion of the sponsor, patients should be called \nback to the site for follow-up immunogenicity assessment",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "7b2c541b-a54c-459f-ba5b-836241df1d60",
                "name": "Nasal Inspection",
                "instanceType": "Activity",
                "description": "Nasal inspection both for IMG and LY900018.",
                "definedProcedures": [
                  {
                    "id": "ec3eb426-efdc-4024-a5f0-c91414e09149",
                    "name": "Nasal Inspection",
                    "procedureType": "Assessment",
                    "code": {
                      "id": "4266601c-4d67-4a7b-9af2-55f08fc7d09e",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Nasal Inspection",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Nasal Inspection",
                    "description": "Inspection of the nasal passages for all patients."
                  }
                ]
              },
              {
                "id": "e111c2d7-73d1-4739-acd7-8c774ea24b98",
                "name": "Vital Signs (Supine Blood Pressure, Pulse Rate, and Body Temperature)",
                "instanceType": "Activity",
                "description": "Time points may be added for each period if warranted and agreed upon between Lilly and the investigator. Predose time point will be between insulin infusion stop and study treatment.",
                "notes": [
                  {
                    "id": "a4b3e51c-2b6f-4f25-a82f-aba5b1ffe515",
                    "text": "Note:  if multiple procedures take place at the same time point, the following order of the procedure should be used:  ECG, vital signs, and venipuncture",
                    "instanceType": "Note"
                  },
                  {
                    "id": "cae525bb-714a-4bbe-9103-7b89750cc704",
                    "text": "Blood pressure and pulse rate should be measured after at least",
                    "instanceType": "Note"
                  },
                  {
                    "id": "22d8d887-2315-4e5b-8a48-0f568e7e3eee",
                    "text": "Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \nposture-induced symptoms",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e2dcedf9-803b-4ea4-89e6-ffe510943a96",
                    "text": "If the patient feels unable to stand, supine \nvital signs only will be recorded",
                    "instanceType": "Note"
                  },
                  {
                    "id": "2efe3186-53f4-497a-b6ef-679ea1fc15ff",
                    "text": "To interpret the results of \nimmunogenicity, a venous blood sample may be collected at the same time points to determine \nthe concentrations of glucagon",
                    "instanceType": "Note"
                  },
                  {
                    "id": "08c3375f-2040-44ad-94ab-ddc31744eb5f",
                    "text": "Study Population\nEligibility of patients for the study will be based on the results of screening medical history, \nphysical examination, vital signs, clinical laboratory tests, and ECG",
                    "instanceType": "Note"
                  },
                  {
                    "id": "f7abedbb-60a4-4890-a7fa-4d0be3761a8e",
                    "text": "Vital Signs\nFor each patient, vital sign measurements should be conducted according to the Schedule of \nActivities",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "986c562e-c944-465d-bc42-2ed8bcbd1d60",
                "name": "Single 12-lead ECG (Local)",
                "instanceType": "Activity",
                "description": "Single 12-lead ECG (Local)",
                "notes": [
                  {
                    "id": "48658673-d4d5-4b34-b1ef-f1d2e6fe66d1",
                    "text": "Note:  if multiple procedures take place at the same time point, the following order of the procedure should be used:  ECG, vital signs, and venipuncture",
                    "instanceType": "Note"
                  },
                  {
                    "id": "3c8aa315-d4c2-4bc2-b182-a5d28098300a",
                    "text": "Single ECGs will be collected and stored locally at the investigatorâs site",
                    "instanceType": "Note"
                  },
                  {
                    "id": "f6150e4e-0a38-4d09-8460-4c040b9dc38d",
                    "text": "Electrocardiograms\nFor each patient, single and triplicate ECGs should be collected according to the Schedule of \nActivities",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "1da547ed-1d71-4fb7-9efb-53ea10f64d58",
                "name": "Triplicate 12-lead ECG (Central)",
                "instanceType": "Activity",
                "description": "Time points may be added for Period 1 and Period 2 if warranted and agreed upon between Lilly and the investigator. Predose time point will be between insulin infusion stop and study treatment.",
                "notes": [
                  {
                    "id": "aed3f28e-bc30-4793-9e46-4834fc6f196c",
                    "text": "Electrocardiograms\nFor each patient, single and triplicate ECGs should be collected according to the Schedule of \nActivities",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "43fed1de-4ec0-4c83-95c6-00e778f42a15",
                "name": "Clinical Serology Tests",
                "instanceType": "Activity",
                "description": "See Appendix 2, Clinical Laboratory Tests, for details."
              },
              {
                "id": "bdbd40f7-1ec7-4662-b995-1e6836e177ba",
                "name": "Clinical Lab Tests (Hematology, Clinical Chemistry, and Urinalysis)",
                "instanceType": "Activity",
                "description": "See Appendix 2, Clinical Laboratory Tests, for details. Patients do not need to fast for samples at screening or follow-up. At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures."
              },
              {
                "id": "04a6ac1c-0537-4d96-8125-ab9ed2aa490e",
                "name": "HbA1c",
                "instanceType": "Activity",
                "description": "See Appendix 2, Clinical Laboratory Tests, for details."
              },
              {
                "id": "e58e3523-ea5a-4ce5-a5fb-19583e88dd55",
                "name": "Pregnancy Test (Female patients of childbearing potential only)",
                "instanceType": "Activity",
                "description": "Serum pregnancy test will be performed at screening. Urine pregnancy test will be performed at every admission period and follow-up visit if applicable.",
                "notes": [
                  {
                    "id": "a8fb9fbc-dd64-4d89-b65d-22f3bc4b034c",
                    "text": "women of childbearing potential participating must test negative for \npregnancy prior to initiation of treatment as indicated by a negative serum \npregnancy test at the screening visit followed by a negative urine \npregnancy test within",
                    "instanceType": "Note"
                  },
                  {
                    "id": "a0c142d8-6690-48b8-ad9b-360e0b146c3b",
                    "text": "Patients who are not enrolled within",
                    "instanceType": "Note"
                  },
                  {
                    "id": "a8ea61b8-5afe-4843-a0cc-6bd6d03ec1ab",
                    "text": "Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \nwill be destroyed within",
                    "instanceType": "Note"
                  },
                  {
                    "id": "72c91075-e271-4724-960b-51d4458e154f",
                    "text": "Every attempt should be made to contact \npatients for the follow-up immunogenicity assessment; however, if patients are unwilling or \nunable to return for the visit, this is not considered a protocol violation",
                    "instanceType": "Note"
                  },
                  {
                    "id": "78152316-2277-45d9-b0e7-6480b09cf024",
                    "text": "male patients: agree to use an effective method of contraception for the \nduration of the study and for",
                    "instanceType": "Note"
                  },
                  {
                    "id": "58c54c35-ca1d-4daf-bebb-454e4257967b",
                    "text": "female patients:",
                    "instanceType": "Note"
                  },
                  {
                    "id": "c3552169-adbf-4f0d-acaa-e3ed6daf1812",
                    "text": "Study Population\nEligibility of patients for the study will be based on the results of screening medical history, \nphysical examination, vital signs, clinical laboratory tests, and ECG",
                    "instanceType": "Note"
                  },
                  {
                    "id": "520b9548-6a8c-40cd-824b-10b9dc02b1bb",
                    "text": "Inclusion Criteria\nPatients are eligible for inclusion in the study only if they meet all of the following criteria at \nscreening and/or enrollment:",
                    "instanceType": "Note"
                  },
                  {
                    "id": "fc002524-32d8-4f43-86ed-7619b0c2a0a2",
                    "text": "Primary Efficacy Assessments\nThe primary efficacy measure is the proportion of patients achieving treatment success, defined \nas either an increase in PG to >",
                    "instanceType": "Note"
                  },
                  {
                    "id": "d9eca839-3248-40f8-ba57-756d02b6af67",
                    "text": "Laboratory Tests\nFor each patient, laboratory tests detailed in Appendix",
                    "instanceType": "Note"
                  },
                  {
                    "id": "3e7d75c9-2402-46ad-9ca4-7d3e5151d37d",
                    "text": "If the \nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \ndefinition of treatment emergent, then, at the discretion of the sponsor, patients should be called \nback to the site for follow-up immunogenicity assessment",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "7c8df6c7-4fd5-4e33-9658-18dd606e5431",
                "name": "FSH (Female patients only)",
                "instanceType": "Activity",
                "description": "When needed to confirm postmenopausal status."
              },
              {
                "id": "8b41e22a-7035-4254-a06a-3d6af6beebbc",
                "name": "Ethanol Testing",
                "instanceType": "Activity",
                "description": "Additional tests can be done at the discretion of the investigator."
              },
              {
                "id": "5f53b92f-257c-40ff-9734-d5205d47f3d5",
                "name": "Urine Drug Screen",
                "instanceType": "Activity",
                "description": "Additional tests can be done at the discretion of the investigator.",
                "definedProcedures": [
                  {
                    "id": "d03fb51b-de6e-49bd-bdd6-7a6869729615",
                    "name": "Urine Collection",
                    "procedureType": "Biospecimen Collection",
                    "code": {
                      "id": "ca5f396a-fdfd-43e7-8865-f905a7b8ade4",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Urine Collection",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Urinalysis/Urine Test",
                    "description": "Collection of urine samples for urinalysis, pregnancy test, and drug screen."
                  }
                ],
                "notes": [
                  {
                    "id": "be7126c9-e5c5-4c9a-8fe6-9dfe29ca3ce6",
                    "text": "women of childbearing potential participating must test negative for \npregnancy prior to initiation of treatment as indicated by a negative serum \npregnancy test at the screening visit followed by a negative urine \npregnancy test within",
                    "instanceType": "Note"
                  },
                  {
                    "id": "df9cbbbf-fc4e-408c-b9a5-63944e6e743e",
                    "text": "Treatment-emergent antidrug antibodies",
                    "instanceType": "Note"
                  },
                  {
                    "id": "51e97d4b-fc74-4b13-aa52-e50f7021d87d",
                    "text": "Study Population\nEligibility of patients for the study will be based on the results of screening medical history, \nphysical examination, vital signs, clinical laboratory tests, and ECG",
                    "instanceType": "Note"
                  },
                  {
                    "id": "75997eee-584b-4523-90de-8fdc33fb010d",
                    "text": "Inclusion Criteria\nPatients are eligible for inclusion in the study only if they meet all of the following criteria at \nscreening and/or enrollment:",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "d538477e-8a88-467a-893f-79b9e8495e53",
                "name": "PK (Glucagon)",
                "instanceType": "Activity",
                "description": "Sampling times are relative to the time of study treatment administration (0 min). Predose time point will be between insulin infusion stop and study treatment."
              },
              {
                "id": "57539182-29aa-4a00-a82e-92dae8ed7575",
                "name": "Plasma Glucose for PD",
                "instanceType": "Activity",
                "description": "-5 mins = stop insulin infusion. Sampling times are relative to the time of study treatment administration (0 min). Predose time point will be between insulin infusion stop and study treatment.",
                "notes": [
                  {
                    "id": "625663a5-d46e-48e6-af9e-e0b2d44dc016",
                    "text": "Efficacy Assessments\nPlasma glucose levels will be measured as described in Section",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "dc8b5f95-7ad3-4263-951c-3d3dd82674c9",
                "name": "Genetic Sample (Stored)",
                "instanceType": "Activity",
                "description": "Single sample for pharmacogenetic analysis taken prior to/on Period 1 Day -1.",
                "definedProcedures": [
                  {
                    "id": "066df21b-8c52-4180-bb69-1222b252c9e5",
                    "name": "Genetic Sample Collection",
                    "procedureType": "Biospecimen Collection",
                    "code": {
                      "id": "be415c7e-2103-46c9-85e3-3164a8b3f35e",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Genetic Sample Collection",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Genetic Sample",
                    "description": "Collection of a single sample for pharmacogenetic analysis."
                  }
                ],
                "notes": [
                  {
                    "id": "7f48bb53-4dcf-4b93-a820-41df12dba166",
                    "text": "a\nSamples for immunogenicity, should be collected every",
                    "instanceType": "Note"
                  },
                  {
                    "id": "62f38824-fab9-40bb-b7f7-1a40835c4834",
                    "text": "Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \nwill be destroyed within",
                    "instanceType": "Note"
                  },
                  {
                    "id": "fada50b6-8bc2-4469-b8ee-d3bcc8565e46",
                    "text": "Certain samples may be \nretained for a longer period, if necessary, to comply with applicable laws, regulations, or \nlaboratory certification standards",
                    "instanceType": "Note"
                  },
                  {
                    "id": "396ac227-b470-4e5c-85fe-5a4b01d50bfc",
                    "text": "The samples will be stored for up to a maximum of",
                    "instanceType": "Note"
                  },
                  {
                    "id": "44370f78-0920-4312-8265-c8f5e33a2960",
                    "text": "To interpret the results of \nimmunogenicity, a venous blood sample may be collected at the same time points to determine \nthe concentrations of glucagon",
                    "instanceType": "Note"
                  },
                  {
                    "id": "3c3c70d3-6c50-4298-a558-189cff736376",
                    "text": "A PK sample may be collected at these \nsame time points",
                    "instanceType": "Note"
                  },
                  {
                    "id": "5b6e7172-2400-44e4-902e-c0dab0352015",
                    "text": "A PK \nsample may be collected at the follow-up immunogenicity assessment",
                    "instanceType": "Note"
                  },
                  {
                    "id": "e3f11e0d-a7c4-4826-a5a3-89c8d88b2ca3",
                    "text": "Bioanalysis\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facility \ndesignated by the sponsor",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "5638a44a-dc63-46b4-b00b-db885c8caa67",
                "name": "Anti-glucagon Antibodies",
                "instanceType": "Activity",
                "description": "In the event of drug hypersensitivity reactions (immediate or non-immediate), samples will be collected as close to event onset as possible, at event resolution, and 30 days following the event. Patients with TE ADA at follow-up/ED will undergo additional follow-up. Refer to Section 9.7.1 for details.",
                "notes": [
                  {
                    "id": "7058c917-c54c-473d-ad11-943def1f9d18",
                    "text": "Treatment-emergent antidrug antibodies",
                    "instanceType": "Note"
                  }
                ]
              },
              {
                "id": "6b9615b3-0ad8-419d-bcdb-d7ef3b79a99f",
                "name": "Clarke Hypoglycemia Awareness Survey",
                "instanceType": "Activity",
                "description": "Clarke Hypoglycemia Awareness Survey"
              },
              {
                "id": "59280ca4-ed25-421b-9554-9a2b833b8b20",
                "name": "Nasal and Non-nasal Score Questionnaire",
                "instanceType": "Activity",
                "description": "Sampling times are relative to the time of study treatment administration (0 min). Questionnaire will be collected in both LY900018 and IMG treatment groups in both periods."
              },
              {
                "id": "f7e38bb5-dfb0-41eb-b9ae-e4751ede0e38",
                "name": "Edinburgh Hypoglycemia Scale: Experimental Hypoglycemia",
                "instanceType": "Activity",
                "description": "Sampling times are relative to the time of study treatment administration (0 min). During hypoglycemia induction will be when PG â¤75 mg/dL. Predose time point will be between insulin infusion stop and study treatment.",
                "definedProcedures": [
                  {
                    "id": "87909368-a64e-4511-8ab2-2a6eefbe76fa",
                    "name": "Edinburgh Hypoglycemia Scale",
                    "procedureType": "Assessment",
                    "code": {
                      "id": "e5cd6854-4091-4e84-9699-ff8bef44470e",
                      "code": "C25218",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Edinburgh Hypoglycemia Scale",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Hypoglycemia Questionnaire",
                    "description": "Assessment of clinical symptoms of hypoglycemia using a questionnaire."
                  }
                ]
              }
            ],
            "epochs": [
              {
                "id": "764a1f6f-274b-43f4-9df0-89f0b4545dd2",
                "name": "Screening",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "85e9b85e-1f0f-4099-9690-2bbba4063401",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "7ec9917b-e5dd-44d6-9b31-a9fbcd993863",
                "name": "Period 1",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "090f0c5c-4e30-488e-9fba-8bf5defdd2d9",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "3d64d9a8-6953-4f11-bdbf-6d65150c86b4",
                "name": "Wash out",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "85020948-a579-489b-b850-74f9a496f400",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "e7dd2b04-3c3c-4f39-a9f3-c35fd6a0ac86",
                "name": "Period 2",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "1765f64f-6cf1-44f8-b6d0-1bba1bc74009",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "b08e6c4d-5987-473d-9447-3e7a20abfefb",
                "name": "Follow-up/ED",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "b843bcda-f39d-414e-999b-36469034effd",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "7d335965-fac7-4587-81d4-8e1fe13187dd",
                "name": "Additional Follow-up for TE ADAa",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "e3ddcd4d-1bcf-4e05-8f6a-b12a7e7a6790",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "washout",
                "name": "Washout",
                "instanceType": "StudyEpoch",
                "description": "Washout - auto-generated from crossover detection",
                "type": {
                  "id": "689b0f4b-2678-48b1-9a19-d8d6cc582b4d",
                  "code": "C98782",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Run-in Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "558c7b03-b221-44de-9fb6-5cbd5d7f35ff",
                "name": "Washout 1",
                "instanceType": "StudyEpoch",
                "description": "Washout period between Period 1 and Period 2",
                "type": {
                  "id": "76a58610-aea1-4cfa-9fa2-0464331e3edb",
                  "code": "C98782",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Run-in Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "9800d761-39d5-4f26-b24c-37eb84751ad2",
                "name": "End of Study",
                "instanceType": "StudyEpoch",
                "description": "End of Study - terminal epoch for subject path completion",
                "type": {
                  "id": "7e0c7149-53d0-4d27-ae3b-7c598f9802e5",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "59262a85-dea6-4c5f-a425-6ca8784b9149",
                "name": "Early Termination",
                "instanceType": "StudyEpoch",
                "description": "Early Termination - terminal epoch for subject path completion",
                "type": {
                  "id": "c6597ad3-7956-49f7-b44a-df1aa9f05b90",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              }
            ],
            "notes": [
              {
                "id": "24435b5b-2e89-4e74-9a34-3ace07ffde0d",
                "text": "a. Samples for immunogenicity, should be collected every 12 weeks (84Â±7 days) until the titer returns to baseline (ie, returns to within a single 2-fold dilution of the baseline titer) or until 1 year after the last dose of study treatment. A time-matched PK (glucagon) sample may be collected at the follow-up immunogenicity assessment(s) if warranted and agreed upon between both the investigator and sponsor.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "e45560ee-8385-4931-bf3a-70fa46c97bbd",
                "text": "Note: If multiple procedures take place at the same time point, the following order of the procedure should be used: ECG, vital signs, and venipuncture. Plasma glucose sample should be collected as close as possible of protocol-specified time point.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "82b904a2-f5c7-481e-ad03-1ae2cad2e4f2",
                "text": "either one highly effective method of contraception or a combination \nof",
                "instanceType": "Note"
              },
              {
                "id": "2ae0a943-d36a-470b-8c63-34c5df7f3eb8",
                "text": "postmenopausal, defined as either:",
                "instanceType": "Note"
              },
              {
                "id": "e3519595-cdaa-4f10-a297-346a9eec3207",
                "text": "cessation of menses for at least",
                "instanceType": "Note"
              },
              {
                "id": "9272cd38-3c84-4138-89dc-7774bd292d5b",
                "text": "if warranted and agreed upon between both the investigator and sponsor",
                "instanceType": "Note"
              },
              {
                "id": "ac9123b8-48c8-43f9-9c50-bb2b5b9a0d23",
                "text": "Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as \nprotocol waivers or exemptions, are not permitted",
                "instanceType": "Note"
              },
              {
                "id": "16daa176-61d6-4942-a691-f24173151bd9",
                "text": "The patient may \nchoose to use a double barrier method of contraception",
                "instanceType": "Note"
              },
              {
                "id": "4b4276bb-93b4-415a-8335-88ec798bc51f",
                "text": "Thus, each barrier method must include use of a \nspermicide",
                "instanceType": "Note"
              },
              {
                "id": "47faead1-f81c-4fc0-9214-196e24eb4528",
                "text": "Concentrations of glucagon will be assayed using a validated liquid chromatography with \ntandem mass spectrometry method",
                "instanceType": "Note"
              },
              {
                "id": "99d8d215-fad8-4c6a-9b25-1f06c37532da",
                "text": "Pharmacodynamics\nAt times specified in the Schedule of Activities",
                "instanceType": "Note"
              }
            ],
            "model": {
              "id": "83f61c86-e501-4ff5-81cc-440f20aadcc5",
              "code": "C49649",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Crossover Study",
              "instanceType": "Code"
            },
            "indications": [
              {
                "id": "8922d2d0-02f5-40c9-be32-8f72ee5c2158",
                "name": "Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
                "isRareDisease": false,
                "instanceType": "Indication",
                "description": "Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus"
              }
            ],
            "procedures": [
              {
                "id": "ccb6022f-e437-49e6-8bbe-87087170479e",
                "name": "Venipuncture",
                "procedureType": "Biospecimen Collection",
                "code": {
                  "id": "8ec1c095-ec5f-4d48-9962-87056a924694",
                  "code": "36415",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collection of venous blood by venipuncture",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Blood Draw",
                "description": "Collection of blood samples for laboratory analysis, including PK, PD, hematology, clinical chemistry, serology, HbA1c, and pregnancy tests."
              },
              {
                "id": "c2b42cf6-59a6-40b9-85f0-f916e021be85",
                "name": "Nasal Glucagon Administration",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "439a2c33-9667-4661-8e9c-04a0dfb26b5f",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Nasal Glucagon Administration",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Nasal Glucagon Admin",
                "description": "Administration of 3 mg LY900018 (nasal glucagon) powder."
              },
              {
                "id": "ce4ecf6c-9780-4e95-bccc-016d1ac67c9e",
                "name": "Intramuscular Glucagon Injection",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "7187f97f-2e58-42d4-9ccf-331e030417c6",
                  "code": "96372",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "IM Glucagon Injection",
                "description": "Administration of 1 mg intramuscular glucagon (IMG)."
              },
              {
                "id": "ad0449e2-a9b5-4971-bfe2-325b8974961c",
                "name": "Vital Signs Measurement",
                "procedureType": "Monitoring",
                "code": {
                  "id": "a721e690-9436-4bc6-8037-32b1f8463310",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Vital Signs Measurement",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Vital Signs",
                "description": "Measurement of supine blood pressure, pulse rate, and body temperature."
              },
              {
                "id": "f1745468-3936-457f-9bde-080f84bb2a44",
                "name": "Electrocardiogram",
                "procedureType": "Diagnostic Procedure",
                "code": {
                  "id": "56d02a10-5abd-4b10-be42-c47bbb7f09ea",
                  "code": "93000",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "ECG",
                "description": "Recording of single 12-lead ECG (local) and triplicate 12-lead ECG (central)."
              },
              {
                "id": "ccffaf1b-c23b-4a7a-96b2-38c7512c2742",
                "name": "Bedside Plasma Glucose Monitoring",
                "procedureType": "Monitoring",
                "code": {
                  "id": "15402baf-87d8-492f-ae33-610d6a9a1165",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Bedside Plasma Glucose Monitoring",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Bedside PG Monitoring",
                "description": "Monitoring of plasma glucose levels at the bedside for safety during hypoglycemia induction and post-treatment."
              },
              {
                "id": "1d5f4151-20ec-4fe4-9a45-19667a1ba90d",
                "name": "Intravenous Glucose Administration",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "f87f6551-2f1d-4f23-93c3-8060502a1724",
                  "code": "C25218",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Intravenous Glucose Administration",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "IV Glucose",
                "description": "Administration of IV glucose if the patient experiences signs and symptoms of severe hypoglycemia requiring intervention."
              }
            ],
            "extensionAttributes": [
              {
                "id": "b34fd29e-589f-488d-b0cd-0ba576c4eb1c",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-timeAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"anchor_llm_1\", \"definition\": \"Administration of study treatment, which is defined as Time = 0 min\", \"anchorType\": \"FirstDose\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Once bedside PG reaches <60 mg/dL, the insulin infusion is stopped and approximately 5 minutes later study drug is administered.  Indicates Time = 0 min.\"}, {\"id\": \"anchor_1\", \"definition\": \"Screening visit\", \"anchorType\": \"Screening\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Screening\\nPeriod\"}, {\"id\": \"anchor_2\", \"definition\": \"Informed consent obtained\", \"anchorType\": \"InformedConsent\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Informed Consent\"}, {\"id\": \"anchor_3\", \"definition\": \"Procedure\", \"anchorType\": \"Custom\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Procedure\"}]"
              },
              {
                "id": "dd69a259-335b-4183-abd0-05ae0d8a03a8",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-repetitions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"rep_daily_1\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"od\"}, {\"id\": \"rep_interval_1\", \"type\": \"Interval\", \"sourceText\": \"tid\"}, {\"id\": \"rep_interval_5\", \"type\": \"Interval\", \"interval\": \"PT15M\", \"minObservations\": 5, \"sourceText\": \"Predose, 15, 30, \\n60, 120, 240 min\"}, {\"id\": \"rep_interval_9\", \"type\": \"Interval\", \"interval\": \"PT5M\", \"minObservations\": 12, \"sourceText\": \"Predose, 5, 10, 15, \\n20, 25, 30, 40, 50, \\n60, 90, 120, 240 \\nmin\"}, {\"id\": \"rep_interval_13\", \"type\": \"Interval\", \"interval\": \"PT15M\", \"minObservations\": 4, \"sourceText\": \"Predose, 15, 30, \\n60, 120 min\"}, {\"id\": \"rep_window_1\", \"type\": \"Continuous\", \"startOffset\": \"P28D\", \"endOffset\": \"P2D\", \"sourceText\": \"Days -28\\nto -2\"}, {\"id\": \"rep_window_5\", \"type\": \"Continuous\", \"sourceText\": \"washout period\"}, {\"id\": \"rep_window_6\", \"type\": \"Continuous\", \"sourceText\": \"Screening\\nPeriod\"}, {\"id\": \"rep_window_10\", \"type\": \"Continuous\", \"sourceText\": \"screening period\"}, {\"id\": \"rep_window_12\", \"type\": \"Continuous\", \"sourceText\": \"washout \\nperiod\"}, {\"id\": \"rep_window_13\", \"type\": \"Continuous\", \"sourceText\": \"treatment period\"}, {\"id\": \"rep_window_17\", \"type\": \"Continuous\", \"sourceText\": \"follow-up period\"}, {\"id\": \"rep_window_18\", \"type\": \"Continuous\", \"sourceText\": \"30 days after\"}, {\"id\": \"rep_window_19\", \"type\": \"Continuous\", \"sourceText\": \"2 days \\nafter\"}, {\"id\": \"rep_window_23\", \"type\": \"Continuous\", \"sourceText\": \"6 hours after\"}, {\"id\": \"rep_window_24\", \"type\": \"Continuous\", \"sourceText\": \"4 hours after\"}]"
              },
              {
                "id": "34500755-2951-47df-a989-081cdbc79e6b",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-samplingConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"sampling_1\", \"activityId\": \"PK_PD_Sampling_Period_1_2\", \"minPerWindow\": 6, \"windowDuration\": \"PT4H\", \"timepoints\": [\"predose\", \"15min\", \"30min\", \"60min\", \"120min\", \"240min\"]}, {\"id\": \"sampling_2\", \"activityId\": \"Immunogenicity_Followup\", \"minPerWindow\": 1, \"windowDuration\": \"P12W\", \"timepoints\": [\"every 12 weeks\"]}, {\"id\": \"sampling_3\", \"activityId\": \"PK_Followup\", \"minPerWindow\": 1, \"windowDuration\": \"P12W\", \"timepoints\": [\"every 12 weeks\"]}]"
              },
              {
                "id": "082c160b-e488-44f1-a49f-f9ceaa573a65",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-crossoverDesign",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"crossover_1\", \"isCrossover\": true, \"numPeriods\": 2, \"numSequences\": 2, \"periods\": [\"Period 1\", \"Period 2\"], \"sequences\": [\"AB\", \"BA\"], \"washoutDuration\": \"3 to 14 days\", \"washoutRequired\": true, \"carryoverPrevention\": \"Patients will be administered a single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14 days.\", \"sourceText\": \"crossover study\"}"
              },
              {
                "id": "3c1082b2-37a3-4245-af4a-7165c829e6b2",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-traversalConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"traversal_crossover_1\", \"requiredSequence\": [\"epoch_1\", \"epoch_2\", \"washout\", \"epoch_4\", \"epoch_end_of_study\"], \"allowEarlyExit\": true, \"exitEpochIds\": [\"epoch_early_termination\"], \"mandatoryVisits\": [\"enc_1\", \"enc_3\"], \"sourceText\": \"crossover study\"}, {\"id\": \"traversal_1\", \"requiredSequence\": [\"epoch_1\", \"epoch_2\", \"epoch_4\", \"epoch_5\", \"epoch_6\"], \"allowEarlyExit\": true, \"exitEpochIds\": [\"epoch_early_termination\"], \"mandatoryVisits\": [\"enc_3\", \"enc_1\"], \"sourceText\": \"[{'condition': 'Insufficient response to glucagon administration', 'path': ['RESCUE_PROCEDURES']}, {'condition': 'Subject meets criteria for discontinuation from the study', 'path': ['EARLY_TERMINATION', 'FOLLOW_UP']}]\"}]"
              },
              {
                "id": "dec8f732-e39c-4eb3-8f67-d426b7b3f658",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-footnoteConditions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"fn_cond_1\", \"conditionType\": \"frequency_daily\", \"text\": \"multiple daily injection of long-acting insulin analog\", \"footnoteId\": \"[A]\", \"structuredCondition\": \"frequency.multiple_daily(injection.long_acting_insulin_analog)\", \"appliesToActivityIds\": [\"act_12\"], \"sourceText\": \"multiple daily injection of long-acting insulin analog\"}, {\"id\": \"fn_cond_2\", \"conditionType\": \"timing_before\", \"text\": \"women of childbearing potential participating must test negative for \\npregnancy prior to initiation of treatment as indicated by a negative serum \\npregnancy test at the screening visit followed by a negative urine \\npregnancy test within\", \"footnoteId\": \"[A]\", \"structuredCondition\": \"eligibility.requires(population.wocbp, test.pregnancy.negative_before_treatment) AND sequence(test.pregnancy.serum@screening, test.pregnancy.urine)\", \"appliesToActivityIds\": [\"act_14\", \"act_26\", \"act_23\"], \"sourceText\": \"women of childbearing potential participating must test negative for \\npregnancy prior to initiation \"}, {\"id\": \"fn_cond_3\", \"conditionType\": \"general\", \"text\": \"either one highly effective method of contraception or a combination \\nof\", \"footnoteId\": \"[B]\", \"structuredCondition\": \"eligibility.requires(contraception.highly_effective OR contraception.combination)\", \"appliesToActivityIds\": [\"Contraception Assessment\"], \"sourceText\": \"either one highly effective method of contraception or a combination \\nof\"}, {\"id\": \"fn_cond_4\", \"conditionType\": \"general\", \"text\": \"postmenopausal, defined as either:\", \"footnoteId\": \"[B]\", \"structuredCondition\": \"eligibility.definition(population.postmenopausal)\", \"appliesToActivityIds\": [\"Eligibility Assessment\"], \"sourceText\": \"postmenopausal, defined as either:\"}, {\"id\": \"fn_cond_5\", \"conditionType\": \"general\", \"text\": \"cessation of menses for at least\", \"footnoteId\": \"[a]\", \"structuredCondition\": \"eligibility.criteria(population.postmenopausal, condition.menses_cessation)\", \"appliesToActivityIds\": [\"Eligibility Assessment\"], \"sourceText\": \"cessation of menses for at least\"}, {\"id\": \"fn_cond_6\", \"conditionType\": \"general\", \"text\": \"if warranted and agreed upon between both the investigator and sponsor\", \"footnoteId\": \"(s)\", \"structuredCondition\": \"condition.if_agreed(investigator, sponsor)\", \"sourceText\": \"if warranted and agreed upon between both the investigator and sponsor\"}, {\"id\": \"fn_cond_7\", \"conditionType\": \"general\", \"text\": \"Predose time point will be\\nbetween insulin infusion \\nstop and study treatment\", \"footnoteId\": \"L.\", \"structuredCondition\": \"timing.between(timepoint.predose, event.insulin_infusion_stop, event.study_treatment_start)\", \"appliesToActivityIds\": [\"act_12\", \"act_14\"], \"sourceText\": \"Predose time point will be\\nbetween insulin infusion \\nstop and study treatment\"}, {\"id\": \"fn_cond_8\", \"conditionType\": \"general\", \"text\": \"a\\nSamples for immunogenicity, should be collected every\", \"footnoteId\": \"s.\", \"structuredCondition\": \"frequency.periodic(collection.sample.immunogenicity)\", \"appliesToActivityIds\": [\"act_29\", \"act_6\"], \"sourceText\": \"a\\nSamples for immunogenicity, should be collected every\"}, {\"id\": \"fn_cond_9\", \"conditionType\": \"timing_after\", \"text\": \"Note:  if multiple procedures take place at the same time point, the following order of the procedure should be used:  ECG, vital signs, and venipuncture\", \"footnoteId\": \"r.\", \"structuredCondition\": \"sequence(ECG, vital_signs, venipuncture)\", \"appliesToActivityIds\": [\"act_18\", \"act_17\"], \"sourceText\": \"Note:  if multiple procedures take place at the same time point, the following order of the procedur\"}, {\"id\": \"fn_cond_10\", \"conditionType\": \"general\", \"text\": \"The nature of any conditions present at the time of the physical examination and any preexisting \\nconditions will be documented\", \"footnoteId\": \"G.\", \"structuredCondition\": \"documentation.required(physical_examination.conditions, preexisting_conditions)\", \"appliesToActivityIds\": [\"act_7\"], \"sourceText\": \"The nature of any conditions present at the time of the physical examination and any preexisting \\nco\"}, {\"id\": \"fn_cond_11\", \"conditionType\": \"general\", \"text\": \"Patients who are not enrolled within\", \"footnoteId\": \"t.\", \"sourceText\": \"Patients who are not enrolled within\", \"appliesToActivityIds\": [\"act_23\"]}, {\"id\": \"fn_cond_12\", \"conditionType\": \"general\", \"text\": \"Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as \\nprotocol waivers or exemptions, are not permitted\", \"footnoteId\": \"y.\", \"sourceText\": \"Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as \\np\"}, {\"id\": \"fn_cond_13\", \"conditionType\": \"general\", \"text\": \"The patient may \\nchoose to use a double barrier method of contraception\", \"footnoteId\": \"d.\", \"sourceText\": \"The patient may \\nchoose to use a double barrier method of contraception\"}, {\"id\": \"fn_cond_14\", \"conditionType\": \"general\", \"text\": \"Thus, each barrier method must include use of a \\nspermicide\", \"footnoteId\": \"d.\", \"sourceText\": \"Thus, each barrier method must include use of a \\nspermicide\"}, {\"id\": \"fn_cond_15\", \"conditionType\": \"general\", \"text\": \"Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \\nwill be destroyed within\", \"footnoteId\": \"y.\", \"sourceText\": \"Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \\n\", \"appliesToActivityIds\": [\"act_6\", \"act_29\", \"grp_2\", \"act_23\"]}, {\"id\": \"fn_cond_16\", \"conditionType\": \"procedure_conditional\", \"text\": \"Certain samples may be \\nretained for a longer period, if necessary, to comply with applicable laws, regulations, or \\nlaboratory certification standards\", \"footnoteId\": \"s.\", \"sourceText\": \"Certain samples may be \\nretained for a longer period, if necessary, to comply with applicable laws, \", \"appliesToActivityIds\": [\"act_29\", \"grp_2\"]}, {\"id\": \"fn_cond_17\", \"conditionType\": \"timing_after\", \"text\": \"Blood pressure and pulse rate should be measured after at least\", \"footnoteId\": \"d.\", \"sourceText\": \"Blood pressure and pulse rate should be measured after at least\", \"appliesToActivityIds\": [\"act_17\"]}, {\"id\": \"fn_cond_18\", \"conditionType\": \"general\", \"text\": \"Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \\nposture-induced symptoms\", \"footnoteId\": \"e.\", \"sourceText\": \"Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \\n\", \"appliesToActivityIds\": [\"act_12\", \"act_17\"]}, {\"id\": \"fn_cond_19\", \"conditionType\": \"general\", \"text\": \"If the patient feels unable to stand, supine \\nvital signs only will be recorded\", \"footnoteId\": \"s.\", \"sourceText\": \"If the patient feels unable to stand, supine \\nvital signs only will be recorded\", \"appliesToActivityIds\": [\"act_17\"]}, {\"id\": \"fn_cond_20\", \"conditionType\": \"general\", \"text\": \"Single ECGs will be collected and stored locally at the investigatorâs site\", \"footnoteId\": \"F.\", \"sourceText\": \"Single ECGs will be collected and stored locally at the investigatorâs site\", \"appliesToActivityIds\": [\"act_18\", \"act_6\"]}, {\"id\": \"fn_cond_21\", \"conditionType\": \"general\", \"text\": \"The central ECG laboratory will perform a basic quality control check\", \"footnoteId\": \"y.\", \"sourceText\": \"The central ECG laboratory will perform a basic quality control check\", \"appliesToActivityIds\": [\"grp_2\"]}, {\"id\": \"fn_cond_22\", \"conditionType\": \"general\", \"text\": \"At a future time, the stored \\nECG data may be overread at the central ECG laboratory for further evaluation of machine-read \\nmeasurements or to meet regulatory requirements\", \"footnoteId\": \"e.\", \"sourceText\": \"At a future time, the stored \\nECG data may be overread at the central ECG laboratory for further eva\", \"appliesToActivityIds\": [\"grp_2\"]}, {\"id\": \"fn_cond_23\", \"conditionType\": \"general\", \"text\": \"Concentrations of glucagon will be assayed using a validated liquid chromatography with \\ntandem mass spectrometry method\", \"footnoteId\": \"r.\", \"sourceText\": \"Concentrations of glucagon will be assayed using a validated liquid chromatography with \\ntandem mass\"}, {\"id\": \"fn_cond_24\", \"conditionType\": \"general\", \"text\": \"The samples will be stored for up to a maximum of\", \"footnoteId\": \"s.\", \"sourceText\": \"The samples will be stored for up to a maximum of\", \"appliesToActivityIds\": [\"act_29\"]}, {\"id\": \"fn_cond_25\", \"conditionType\": \"general\", \"text\": \"To interpret the results of \\nimmunogenicity, a venous blood sample may be collected at the same time points to determine \\nthe concentrations of glucagon\", \"footnoteId\": \"n.\", \"sourceText\": \"To interpret the results of \\nimmunogenicity, a venous blood sample may be collected at the same time\", \"appliesToActivityIds\": [\"act_29\", \"act_17\", \"act_6\"]}, {\"id\": \"fn_cond_26\", \"conditionType\": \"general\", \"text\": \"A PK sample may be collected at these \\nsame time points\", \"footnoteId\": \"t.\", \"sourceText\": \"A PK sample may be collected at these \\nsame time points\", \"appliesToActivityIds\": [\"act_29\", \"act_6\"]}, {\"id\": \"fn_cond_27\", \"conditionType\": \"general\", \"text\": \"Treatment-emergent antidrug antibodies\", \"footnoteId\": \"r.\", \"sourceText\": \"Treatment-emergent antidrug antibodies\", \"appliesToActivityIds\": [\"act_30\", \"act_14\", \"act_26\"]}, {\"id\": \"fn_cond_28\", \"conditionType\": \"general\", \"text\": \"A PK \\nsample may be collected at the follow-up immunogenicity assessment\", \"footnoteId\": \"t.\", \"sourceText\": \"A PK \\nsample may be collected at the follow-up immunogenicity assessment\", \"appliesToActivityIds\": [\"act_15\", \"act_29\", \"act_6\"]}, {\"id\": \"fn_cond_29\", \"conditionType\": \"general\", \"text\": \"Every attempt should be made to contact \\npatients for the follow-up immunogenicity assessment; however, if patients are unwilling or \\nunable to return for the visit, this is not considered a protocol violation\", \"footnoteId\": \"r.\", \"sourceText\": \"Every attempt should be made to contact \\npatients for the follow-up immunogenicity assessment; howev\", \"appliesToActivityIds\": [\"act_15\", \"act_23\"]}, {\"id\": \"fn_cond_30\", \"conditionType\": \"general\", \"text\": \"male patients: agree to use an effective method of contraception for the \\nduration of the study and for\", \"footnoteId\": \"[2]\", \"sourceText\": \"male patients: agree to use an effective method of contraception for the \\nduration of the study and \", \"appliesToActivityIds\": [\"act_14\", \"act_23\"]}, {\"id\": \"fn_cond_31\", \"conditionType\": \"general\", \"text\": \"female patients:\", \"footnoteId\": \"[3]\", \"sourceText\": \"female patients:\", \"appliesToActivityIds\": [\"act_23\"]}, {\"id\": \"fn_cond_32\", \"conditionType\": \"general\", \"text\": \"Study Population\\nEligibility of patients for the study will be based on the results of screening medical history, \\nphysical examination, vital signs, clinical laboratory tests, and ECG\", \"footnoteId\": \"6.\", \"sourceText\": \"Study Population\\nEligibility of patients for the study will be based on the results of screening med\", \"appliesToActivityIds\": [\"act_17\", \"grp_2\", \"act_5\", \"grp_1\", \"act_23\", \"act_14\", \"act_7\", \"act_26\"]}, {\"id\": \"fn_cond_33\", \"conditionType\": \"timing_after\", \"text\": \"Inclusion Criteria\\nPatients are eligible for inclusion in the study only if they meet all of the following criteria at \\nscreening and/or enrollment:\", \"footnoteId\": \"1.\", \"sourceText\": \"Inclusion Criteria\\nPatients are eligible for inclusion in the study only if they meet all of the fol\", \"appliesToActivityIds\": [\"act_14\", \"act_26\", \"act_23\"]}, {\"id\": \"fn_cond_34\", \"conditionType\": \"general\", \"text\": \"Study Assessments and Procedures\\nSection\", \"footnoteId\": \"9.\", \"sourceText\": \"Study Assessments and Procedures\\nSection\", \"appliesToActivityIds\": [\"act_14\", \"grp_1\", \"act_15\"]}, {\"id\": \"fn_cond_35\", \"conditionType\": \"general\", \"text\": \"Efficacy Assessments\\nPlasma glucose levels will be measured as described in Section\", \"footnoteId\": \"1.\", \"sourceText\": \"Efficacy Assessments\\nPlasma glucose levels will be measured as described in Section\", \"appliesToActivityIds\": [\"act_15\", \"grp_1\", \"act_28\"]}, {\"id\": \"fn_cond_36\", \"conditionType\": \"general\", \"text\": \"Primary Efficacy Assessments\\nThe primary efficacy measure is the proportion of patients achieving treatment success, defined \\nas either an increase in PG to >\", \"footnoteId\": \"1.\", \"sourceText\": \"Primary Efficacy Assessments\\nThe primary efficacy measure is the proportion of patients achieving tr\", \"appliesToActivityIds\": [\"act_14\", \"grp_1\", \"act_15\", \"act_23\"]}, {\"id\": \"fn_cond_37\", \"conditionType\": \"general\", \"text\": \"Secondary Efficacy Assessments\\nSecondary efficacy measures will be determined from the pharmacodynamic\", \"footnoteId\": \"2.\", \"sourceText\": \"Secondary Efficacy Assessments\\nSecondary efficacy measures will be determined from the pharmacodynam\", \"appliesToActivityIds\": [\"act_15\", \"grp_1\", \"act_4\"]}, {\"id\": \"fn_cond_38\", \"conditionType\": \"general\", \"text\": \"Exploratory Efficacy Assessments\\nSubjective hypoglycemia symptoms will be assessed using a self-reported assessment tool\", \"footnoteId\": \"3.\", \"sourceText\": \"Exploratory Efficacy Assessments\\nSubjective hypoglycemia symptoms will be assessed using a self-repo\", \"appliesToActivityIds\": [\"act_12\", \"grp_1\", \"act_15\"]}, {\"id\": \"fn_cond_39\", \"conditionType\": \"general\", \"text\": \"Insulin-induced Hypoglycemia\\nA study investigator, or qualified designee, must be present at the bedside for clinical \\nassessments of the patient during the insulin infusion and for the\", \"footnoteId\": \"1.\", \"sourceText\": \"Insulin-induced Hypoglycemia\\nA study investigator, or qualified designee, must be present at the bed\", \"appliesToActivityIds\": [\"act_12\", \"act_13\", \"grp_1\", \"act_15\", \"act_14\"]}, {\"id\": \"fn_cond_40\", \"conditionType\": \"general\", \"text\": \"Treatment of Overdose\\nFor the purposes of this study, an overdose of LY\", \"footnoteId\": \"4.\", \"sourceText\": \"Treatment of Overdose\\nFor the purposes of this study, an overdose of LY\", \"appliesToActivityIds\": [\"act_14\"]}, {\"id\": \"fn_cond_41\", \"conditionType\": \"general\", \"text\": \"Laboratory Tests\\nFor each patient, laboratory tests detailed in Appendix\", \"footnoteId\": \"1.\", \"sourceText\": \"Laboratory Tests\\nFor each patient, laboratory tests detailed in Appendix\", \"appliesToActivityIds\": [\"grp_2\", \"act_23\"]}, {\"id\": \"fn_cond_42\", \"conditionType\": \"general\", \"text\": \"Vital Signs\\nFor each patient, vital sign measurements should be conducted according to the Schedule of \\nActivities\", \"footnoteId\": \"2.\", \"sourceText\": \"Vital Signs\\nFor each patient, vital sign measurements should be conducted according to the Schedule \", \"appliesToActivityIds\": [\"act_17\"]}, {\"id\": \"fn_cond_43\", \"conditionType\": \"general\", \"text\": \"Electrocardiograms\\nFor each patient, single and triplicate ECGs should be collected according to the Schedule of \\nActivities\", \"footnoteId\": \"3.\", \"sourceText\": \"Electrocardiograms\\nFor each patient, single and triplicate ECGs should be collected according to the\", \"appliesToActivityIds\": [\"act_19\", \"act_18\", \"act_6\"]}, {\"id\": \"fn_cond_44\", \"conditionType\": \"general\", \"text\": \"Bioanalysis\\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facility \\ndesignated by the sponsor\", \"footnoteId\": \"1.\", \"sourceText\": \"Bioanalysis\\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facilit\", \"appliesToActivityIds\": [\"act_29\", \"grp_2\"]}, {\"id\": \"fn_cond_45\", \"conditionType\": \"general\", \"text\": \"Pharmacodynamics\\nAt times specified in the Schedule of Activities\", \"footnoteId\": \"7.\", \"sourceText\": \"Pharmacodynamics\\nAt times specified in the Schedule of Activities\"}, {\"id\": \"fn_cond_46\", \"conditionType\": \"general\", \"text\": \"Immunogenicity Assessments\\nAt the visits and times specified in the Schedule of Activities\", \"footnoteId\": \"1.\", \"sourceText\": \"Immunogenicity Assessments\\nAt the visits and times specified in the Schedule of Activities\", \"appliesToActivityIds\": [\"act_15\", \"grp_1\"]}, {\"id\": \"fn_cond_47\", \"conditionType\": \"general\", \"text\": \"If the \\nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \\ndefinition of treatment emergent, then, at the discretion of the sponsor, patients should be called \\nback to the site for follow-up immunogenicity assessment\", \"footnoteId\": \"6.\", \"sourceText\": \"If the \\nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \\nde\", \"appliesToActivityIds\": [\"act_15\", \"act_14\", \"act_23\"]}]"
              },
              {
                "id": "f6db62ba-2795-411f-b234-532715c91654",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-endpointAlgorithms",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"ep_1\", \"name\": \"Treatment Success for Hypoglycemia Recovery\", \"endpointType\": \"Primary\", \"inputs\": [\"PG\", \"glucagon_admin_time\", \"PG_nadir\"], \"timeWindow\": {\"reference\": \"glucagon administration\", \"duration\": \"PT30M\"}, \"algorithm\": \"(PG_at_t >= 70) OR (PG_at_t - PG_nadir >= 20), where t is within 30 minutes of glucagon administration. PG_nadir is the minimum PG at the time of or within 10 minutes following glucagon administration.\", \"successCriteria\": \"A patient achieves treatment success if, within 30 minutes of glucagon administration, their Plasma Glucose (PG) is â¥70 mg/dL OR their PG has increased by â¥20 mg/dL from nadir.\", \"sourceText\": \"Treatment success is defined as either an increase in PG to â¥70 mg/dL or an increase of â¥20 mg/dL from PG nadir within 30 minutes after receiving study treatment. The nadir is defined as the minimum P\"}, {\"id\": \"ep_2\", \"name\": \"Change from Baseline in Plasma Glucose\", \"endpointType\": \"Secondary\", \"inputs\": [\"PG_baseline\", \"PG_post_baseline\"], \"timeWindow\": {\"reference\": \"Not specified\", \"duration\": \"Not specified\"}, \"algorithm\": \"PG_post_baseline - PG_baseline\", \"successCriteria\": \"Not specified in the provided text.\", \"sourceText\": \"Secondary efficacy measures will be determined from the pharmacodynamic (PD) characterization of PG profiles, including evaluation of change from baseline PG concentrations.\"}, {\"id\": \"ep_3\", \"name\": \"Assessment of Subjective Hypoglycemia Symptoms\", \"endpointType\": \"Exploratory\", \"inputs\": [\"Edinburgh Hypoglycemia Scale score\"], \"timeWindow\": {\"reference\": \"Multiple time points including initiation of hypoglycemia induction and post-glucagon administration\", \"duration\": \"Not specified\"}, \"algorithm\": \"Assessment via survey tool. Specific calculation (e.g., change from baseline) is not defined.\", \"successCriteria\": \"Not specified in the provided text.\", \"sourceText\": \"Subjective hypoglycemia symptoms will be assessed using a self-reported assessment tool (Edinburgh Hypoglycemia Scale; Appendix 7) during the initiation of the hypoglycemia induction, as well as at va\"}, {\"id\": \"ep_4\", \"name\": \"Assessment of Hypoglycemia Awareness\", \"endpointType\": \"Exploratory\", \"inputs\": [\"Clarke Hypoglycemia Awareness Survey score\"], \"timeWindow\": {\"reference\": \"Period 1 Day -1\", \"duration\": \"Single time point\"}, \"algorithm\": \"Assessment via survey tool. Specific calculation is not defined.\", \"successCriteria\": \"Not specified in the provided text.\", \"sourceText\": \"The ability of the patient to identify hypoglycemic symptoms and describe their frequency will be captured at Period 1 Day -1 (see Schedule of Activities; Section 2). This self-report assessment will \"}]"
              },
              {
                "id": "0d761c7d-499f-445b-8342-06cb7dadcd5e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-derivedVariables",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dv_1\", \"name\": \"Treatment Success\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Plasma Glucose (PG)\"], \"derivationRule\": \"A binary variable indicating treatment success, defined as either an increase in PG to >70 mg/dL or an increase of >20 mg/dL from nadir PG, assessed at any time point within 30 minutes after administration of glucagon.\", \"baselineDefinition\": \"The baseline for the change calculation component is the PG nadir, defined as the lowest PG value reached during the insulin-induced hypoglycemia phase prior to glucagon administration.\", \"baselineVisit\": \"Predose (Time 0)\", \"analysisWindow\": \"Within 30 minutes after administration of glucagon\", \"unit\": \"Categorical (Success/Failure)\"}, {\"id\": \"dv_2\", \"name\": \"Change from Baseline in Plasma Glucose\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"Plasma Glucose (PG)\"], \"derivationRule\": \"PG value at a given post-dose time point - PG value at baseline.\", \"baselineDefinition\": \"The PG value at the time of glucagon administration (Time 0), which corresponds to the PG nadir.\", \"baselineVisit\": \"Predose (Time 0)\", \"analysisWindow\": \"Post-dose time points including 15, 30, 60, and 120 minutes.\", \"unit\": \"mg/dL\"}, {\"id\": \"dv_3\", \"name\": \"Probable symptomatic hypoglycemia\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Hypoglycemia symptoms\", \"Plasma Glucose (PG)\"], \"derivationRule\": \"An event is classified as 'Probable symptomatic hypoglycemia' if symptoms of hypoglycemia were present, but a PG measurement was not reported.\", \"analysisWindow\": \"Entire study period\", \"unit\": \"Categorical (Yes/No)\"}, {\"id\": \"dv_4\", \"name\": \"Overall (or total) hypoglycemia\", \"variableType\": \"Composite\", \"sourceVariables\": [\"Documented hypoglycemia\", \"Probable symptomatic hypoglycemia\", \"Severe hypoglycemia\"], \"derivationRule\": \"Combines cases of documented hypoglycemia and probable symptomatic hypoglycemia, including severe hypoglycemia. Relative hypoglycemia is excluded. Each event is counted only once in this category.\", \"analysisWindow\": \"Entire study period\", \"unit\": \"Categorical (Yes/No)\"}, {\"id\": \"dv_5\", \"name\": \"Elevated Alanine Aminotransferase (ALT)\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Alanine Aminotransferase (ALT)\", \"ALT Upper Limit of Normal (ULN)\"], \"derivationRule\": \"ALT value is â¥ 3 times the Upper Limit of Normal (ULN).\", \"analysisWindow\": \"Entire study period\", \"unit\": \"Categorical (Yes/No)\"}, {\"id\": \"dv_6\", \"name\": \"Elevated Alkaline Phosphatase (ALP)\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Alkaline Phosphatase (ALP)\", \"ALP Upper Limit of Normal (ULN)\"], \"derivationRule\": \"ALP value is â¥ 2 times the Upper Limit of Normal (ULN).\", \"analysisWindow\": \"Entire study period\", \"unit\": \"Categorical (Yes/No)\"}, {\"id\": \"dv_7\", \"name\": \"Elevated Total Bilirubin (TBL)\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Total Bilirubin (TBL)\", \"TBL Upper Limit of Normal (ULN)\"], \"derivationRule\": \"TBL value is â¥ 2 times the Upper Limit of Normal (ULN).\", \"analysisWindow\": \"Entire study period\", \"unit\": \"Categorical (Yes/No)\"}]"
              },
              {
                "id": "2cf48fcf-ecda-4206-a853-b4acddfdd599",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-stateMachine",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"sm_1\", \"initialState\": \"Screening\", \"terminalStates\": [\"Completed\", \"Discontinued\", \"Withdrawn\", \"Death\", \"LostToFollowUp\"], \"states\": [\"OnTreatment\", \"Discontinued\", \"Withdrawn\", \"Death\"], \"transitions\": [{\"fromState\": \"OnTreatment\", \"toState\": \"Discontinued\", \"trigger\": \"Discontinuation from treatment\"}, {\"fromState\": \"OnTreatment\", \"toState\": \"OnTreatment\", \"trigger\": \"Enter washout period\", \"guardCondition\": \"period_complete AND NOT last_period\"}]}"
              },
              {
                "id": "61b97623-8c95-43c1-81bf-f368eb0b9e69",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-dosingRegimens",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dosing_1\", \"treatmentName\": \"LY900018 with\", \"frequency\": \"QD\", \"route\": \"Intranasal\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}], \"sourceText\": \"tration of glucagon. The nadir is defined as the minimum PG value at the time of or within 10 minutes following glucagon administration. Secondary ï· To compare the safety and tolerability of 3 mg LY90\"}, {\"id\": \"dosing_2\", \"treatmentName\": \"LY900018 and\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}], \"sourceText\": \"adults with T1DM and T2DM: Study IGBC, Study I8R-MC-IGBA (IGBA), and an actual use study (Study I8R-MC-B002 [B002]). Studies IGBC and IGBA demonstrated comparable safety and efficacy between 3 mg LY90\"}, {\"id\": \"dosing_3\", \"treatmentName\": \"LY900018 or\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 60.0, \"unit\": \"mg\"}], \"sourceText\": \"be conducted to monitor bedside PG for safety. The insulin infusion will be stopped once the PG level reaches <60 mg/dL and approximately 5 minutes later patients will be administered either 3 mg LY90\"}, {\"id\": \"dosing_4\", \"treatmentName\": \"Dosage Levels\", \"frequency\": \"QD\", \"route\": \"IM\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"g glucagon administered IM (comparator). Table IGBJ.2 shows the study treatment information. Table IGBJ.2. Study Treatments Treatment Name LY900018 GlucaGen Dosage Formulation Dry powder Dry powder Do\"}, {\"id\": \"dosing_llm_1\", \"treatmentName\": \"Insulin\", \"frequency\": \"QD\", \"route\": \"IV\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 2.0, \"unit\": \"mU/kg/min\", \"description\": \"starting infusion rate\"}, {\"amount\": 4.0, \"unit\": \"mU/kg/min\", \"description\": \"maximum infusion rate\"}], \"durationDescription\": \"Until plasma glucose is <50 mg/dL\", \"titrationSchedule\": \"The infusion will be initiated at a rate of 2.0 mU/kg/min and may be increased every 15 minutes to a maximum of 4.0 mU/kg/min until the plasma glucose is <50 mg/dL.\"}, {\"id\": \"dosing_llm_2\", \"treatmentName\": \"Nasal Glucagon (LY900018)\", \"frequency\": \"QD\", \"route\": \"Intranasal\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}], \"durationDescription\": \"Single administration\", \"doseModifications\": [\"If the patientâs plasma glucose (PG) does not increase to â¥70 mg/dL or by â¥20 mg/dL from the nadir PG within 15 minutes of glucagon administration, a second dose of the same glucagon will be administered.\", \"If the patientâs PG does not increase to â¥70 mg/dL or by â¥20 mg/dL from the nadir PG within 15 minutes of the second glucagon administration, IV glucose will be administered.\"]}, {\"id\": \"dosing_llm_3\", \"treatmentName\": \"Intramuscular Glucagon\", \"frequency\": \"QD\", \"route\": \"IM\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}], \"durationDescription\": \"Single administration\", \"doseModifications\": [\"If the patientâs plasma glucose (PG) does not increase to â¥70 mg/dL or by â¥20 mg/dL from the nadir PG within 15 minutes of glucagon administration, a second dose of the same glucagon will be administered.\", \"If the patientâs PG does not increase to â¥70 mg/dL or by â¥20 mg/dL from the nadir PG within 15 minutes of the second glucagon administration, IV glucose will be administered.\"]}, {\"id\": \"dosing_llm_4\", \"treatmentName\": \"IV glucose\", \"frequency\": \"PRN\", \"route\": \"IV\", \"startDay\": 1, \"durationDescription\": \"As needed for rescue\", \"doseModifications\": [\"Administered if the patientâs plasma glucose (PG) does not increase to â¥70 mg/dL or by â¥20 mg/dL from the nadir PG within 15 minutes of the second glucagon administration.\"]}]"
              },
              {
                "id": "8ece7e36-9efe-4a51-a072-c329e2c3ada0",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-visitWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"visit_1\", \"visitName\": \"screening\", \"targetDay\": -14, \"windowBefore\": 28, \"windowAfter\": 28, \"isRequired\": true, \"visitNumber\": 1, \"sourceText\": \"Patients will undergo a screening examination within 28 days prior to enrollment. Patients will be administered a single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14\"}, {\"id\": \"visit_llm_2\", \"visitName\": \"Period 1 - Day -1\", \"targetDay\": -1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 2, \"epoch\": \"Treatment\"}, {\"id\": \"visit_7\", \"visitName\": \"baseline\", \"targetDay\": 0, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 3, \"sourceText\": \"Samples for immunogenicity, should be collected every 12 weeks (84Â±7 days) until the titer returns to baseline (ie, returns to within a single 2-fold dilution of the baseline titer) or until 1 year af\"}, {\"id\": \"visit_2\", \"visitName\": \"Early Termination\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 4, \"epoch\": \"Treatment\", \"sourceText\": \"single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14 days. Patients will return for a follow-up visit 26 to 30 days after the last study treatment. Number of Patients\"}, {\"id\": \"visit_llm_4\", \"visitName\": \"Period 2 - Day -1\", \"targetDay\": 8, \"windowBefore\": 5, \"windowAfter\": 6, \"isRequired\": true, \"visitNumber\": 4, \"epoch\": \"Treatment\"}, {\"id\": \"visit_llm_5\", \"visitName\": \"Period 2 - Day 1\", \"targetDay\": 9, \"windowBefore\": 5, \"windowAfter\": 6, \"isRequired\": true, \"visitNumber\": 5, \"epoch\": \"Treatment\"}, {\"id\": \"visit_4\", \"visitName\": \"Follow-up\", \"targetDay\": 365, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 7, \"sourceText\": \"a follow-up visit 26 to 30 days after the last study treatment. Number of Patients: Seventy five patients may be enrolled in order to have at least 66 patients (at least 30 patients with T1DM and\"}]"
              },
              {
                "id": "e03a030e-3f5d-4ae2-8b16-1a5e70777847",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-randomizationScheme",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"randomization_1\", \"ratio\": \"1:1\", \"method\": \"dynamic randomization\", \"centralRandomization\": true, \"sourceText\": \"I8R-JE-IGBJ(a) Clinical Pharmacology Protocol\\nPage 23\\nLY900018\\n5. Study Design\\n5.1.\\nOverall Design\\nThis is a Phase 3, multicenter, randomized, open-label, active comparator, single-dose, 2-period, \\n2-\"}"
              }
            ],
            "administrations": [
              {
                "id": "1a49f517-bdc0-4194-b3d3-2742b5d6e500",
                "name": "LY900018 with Administration",
                "instanceType": "Administration",
                "dose": "1.0 mg / 3.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "70be9764-88b7-46e9-a79b-ba8a641a937e",
                  "code": "Intranasal",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Intranasal",
                  "instanceType": "Code"
                },
                "description": "tration of glucagon. The nadir is defined as the minimum PG value at the time of or within 10 minutes following glucagon administration. Secondary ï· To compare the safety and tolerability of 3 mg LY90"
              },
              {
                "id": "0ed1665c-04b1-4ece-975a-9d915399e9a4",
                "name": "LY900018 and Administration",
                "instanceType": "Administration",
                "dose": "1.0 mg / 3.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "b3a81bd9-3096-4237-8ac8-e0568b4e2d70",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": "adults with T1DM and T2DM: Study IGBC, Study I8R-MC-IGBA (IGBA), and an actual use study (Study I8R-MC-B002 [B002]). Studies IGBC and IGBA demonstrated comparable safety and efficacy between 3 mg LY90"
              },
              {
                "id": "421b5908-1223-4bd0-9492-4a7a5d477e98",
                "name": "LY900018 or Administration",
                "instanceType": "Administration",
                "dose": "1.0 mg / 3.0 mg / 60.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "dc8a4dec-71eb-404d-9bb7-d405ee3edaa2",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": "be conducted to monitor bedside PG for safety. The insulin infusion will be stopped once the PG level reaches <60 mg/dL and approximately 5 minutes later patients will be administered either 3 mg LY90"
              },
              {
                "id": "bd0bb794-87c0-4a3b-bff1-5dfb0093634d",
                "name": "Dosage Levels Administration",
                "instanceType": "Administration",
                "dose": "3.0 mg / 1.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "f7a56724-7459-4462-93b7-ef488bde2aec",
                  "code": "IM",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IM",
                  "instanceType": "Code"
                },
                "description": "g glucagon administered IM (comparator). Table IGBJ.2 shows the study treatment information. Table IGBJ.2. Study Treatments Treatment Name LY900018 GlucaGen Dosage Formulation Dry powder Dry powder Do"
              },
              {
                "id": "aec626ea-94ae-4c18-8b50-f5ee855f5556",
                "name": "Insulin Administration",
                "instanceType": "Administration",
                "dose": "2.0 mU/kg/min / 4.0 mU/kg/min",
                "doseFrequency": "QD",
                "route": {
                  "id": "c75e20c9-f9dd-460c-afa9-3e2a65a3dec4",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                },
                "duration": "Until plasma glucose is <50 mg/dL"
              },
              {
                "id": "ff291763-84e0-4b78-82e3-77d2f1be8f3c",
                "name": "Nasal Glucagon (LY900018) Administration",
                "instanceType": "Administration",
                "dose": "3.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "98551ce5-6bd8-4209-993b-ef6a56b3ff07",
                  "code": "Intranasal",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Intranasal",
                  "instanceType": "Code"
                },
                "duration": "Single administration"
              },
              {
                "id": "4386049d-3c33-4ee2-ba77-6e43743a793a",
                "name": "Intramuscular Glucagon Administration",
                "instanceType": "Administration",
                "dose": "1.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "b10980a6-537d-4abc-936c-0e670b65a6dd",
                  "code": "IM",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IM",
                  "instanceType": "Code"
                },
                "duration": "Single administration"
              },
              {
                "id": "53e1e042-95f6-47a1-8b58-c229e13faefd",
                "name": "IV glucose Administration",
                "instanceType": "Administration",
                "doseFrequency": "PRN",
                "route": {
                  "id": "05d15220-31d2-40a6-bfe0-eaf37a2d39c5",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                },
                "duration": "As needed for rescue"
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "95976b48-8b4d-4b85-88ea-89800362f51b",
            "text": "A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
            "type": {
              "id": "9096b33a-a4af-4ee6-a917-eb49e32fcecf",
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "826cbc82-2a0f-49bc-bb48-cdf6546ee47e",
            "text": "I8R-JE-IGBJ",
            "instanceType": "StudyIdentifier",
            "scopeId": "7394572c-6bf3-4999-a10a-b26425436060",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "da61a1cf-8e2e-4fff-86da-91c175530a19",
            "text": "NCT03421379",
            "instanceType": "StudyIdentifier",
            "scopeId": "d5b82ed6-605f-495e-a8c3-0b9747e4c43f",
            "type": {
              "code": "C172240",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinicaltrials.gov Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "979753b5-40c3-4d5c-baf6-48ca9c178133",
            "text": "LY900018",
            "instanceType": "StudyIdentifier",
            "scopeId": "7394572c-6bf3-4999-a10a-b26425436060",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          }
        ],
        "organizations": [
          {
            "id": "7394572c-6bf3-4999-a10a-b26425436060",
            "name": "Eli Lilly and Company",
            "type": {
              "id": "bd1c4a89-7817-43ea-bd0b-76a431c80340",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "Eli Lilly and Company",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "7451008b-614f-4f4b-bb72-d1cd3e858f28",
            "name": "Eli Lilly Japan K.K",
            "type": {
              "id": "6d0cdf9e-4bac-48cd-9e4a-ca16cad9f8a0",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "Eli Lilly Japan K.K",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "d5b82ed6-605f-495e-a8c3-0b9747e4c43f",
            "name": "ClinicalTrials.gov",
            "type": {
              "id": "da758ce7-95b5-4dc0-9cd1-ad792f83c752",
              "code": "C19326",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Healthcare Facility",
              "instanceType": "Code"
            },
            "identifier": "ClinicalTrials.gov",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          }
        ],
        "studyPhase": {
          "id": "6d5381ba-bb75-4de6-9fad-49b777a9c1a4",
          "code": "Phase3",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Phase3",
          "instanceType": "Code"
        },
        "eligibilityCriterionItems": [
          {
            "id": "4dafcf5f-11d2-468c-abf4-97d3017dff4e",
            "name": "Criterion 1",
            "text": "have had a diagnosis of either:\n[1a] T1DM based on the World Health Organization (WHO) diagnostic criteria, and have been on the following daily insulin therapy for at least 1 year\n[A] multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or \n[B] continuous subcutaneous insulin infusion (CSII)\nOr\n[1b] T2DM based on the WHO diagnostic criteria, and have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n[A] insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n[B] OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "00596f71-9604-4622-b110-5da85ac18704",
            "name": "Criterion 2",
            "text": "male patients: agree to use an effective method of contraception for the duration of the study and for 28 days following the last study treatment",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "3dca4c67-73d3-4c1a-9618-48d8c066e263",
            "name": "Criterion 3",
            "text": "female patients:\n[3a] women of childbearing potential who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same sex relationship without sexual relationships with males. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception. \n[3b] otherwise, women of childbearing potential participating must agree to use one highly effective method (less than 1% failure rate) of contraception, or a combination of 2 effective methods of contraception for the entirety of the study.\n[A] women of childbearing potential participating must test negative for pregnancy prior to initiation of treatment as indicated by a negative serum pregnancy test at the screening visit followed by a negative urine pregnancy test within 24 hours prior to exposure.\n[B] either one highly effective method of contraception or a combination of 2 effective methods of contraception will be used. The patient may choose to use a double barrier method of contraception. Barrier protection methods without concomitant use of a spermicide are not a reliable or acceptable method. Thus, each barrier method must include use of a spermicide. It should be noted that the use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these methods are combined.\n[3c] women not of childbearing potential may participate, and include those who are:\n[A] infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis\nOr\n[B] postmenopausal, defined as either:\n[i] a woman at least 50 years of age with an intact uterus, not on hormone therapy, who has had either:\n[a] cessation of menses for at least 1 year, or\n[b] at least 6 months of spontaneous amenorrhea with a follicle-stimulating hormone >40 mIU/mL; or\n[ii] a woman 55 or older not on hormone therapy, who has had at least 6 months of spontaneous amenorrhea, or\n[iii] a woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "f7716093-e22f-4db2-9509-52bc34858d03",
            "name": "Criterion 4",
            "text": "are between 18 and 64 years old for T1DM, or between 20 and 70 years old for T2DM at the time of informed consent",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "9e270e37-9cc1-4028-b2c8-afc868b1a59f",
            "name": "Criterion 5",
            "text": "have a body mass index of 18.5 to 30.0 kg/m2 for T1DM, or 18.5 to 35.0 kg/m2 for T2DM at the time of screening",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "5cbb9ea9-7d38-45de-872d-e8af4623b868",
            "name": "Criterion 6",
            "text": "have a hemoglobin A1c value â¤10% at the time of screening",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "7a8454a8-1084-4296-b25f-f3c847ea4820",
            "name": "Criterion 7",
            "text": "have clinical laboratory test results within normal reference range (except for glycemic parameters) for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "4714e10a-9052-4df6-8f5e-be77c064d27e",
            "name": "Criterion 8",
            "text": "have venous access sufficient to allow for blood sampling and administration of insulin for IV administration as per the protocol",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "74e45f0f-d612-490f-a53a-d51be516dfd7",
            "name": "Criterion 9",
            "text": "are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a179a55f-5f37-4e9f-8c7b-eb467ef43ab6",
            "name": "Criterion 10",
            "text": "are able and willing to give signed informed consent",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "42d532d2-1862-445f-924a-f82b07e7e45f",
            "name": "Criterion 11",
            "text": "are investigative site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, biological or legal guardian, child, or sibling",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "6183ac6b-8b5b-487b-a44a-a41f6cdaa1c4",
            "name": "Criterion 12",
            "text": "are Lilly employees",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "60bb90fd-49fe-4b08-9d98-74a82136b7e1",
            "name": "Criterion 13",
            "text": "are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "fb1e0cc6-572a-41cb-b24b-65d36c8134fe",
            "name": "Criterion 14",
            "text": "have participated, within the last 4 months, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 4 months or 5 half-lives (whichever is longer) should have passed from the last dose of investigational product",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "d2cfb060-7e26-45aa-88de-a534164bde02",
            "name": "Criterion 15",
            "text": "have previously completed or withdrawn from this study or any other study investigating LY900018, and have previously received LY900018",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "f861389d-1aa3-4a5a-8402-0b34818b4d37",
            "name": "Criterion 16",
            "text": "have known allergies or sensitivity to LY900018, glucagon, related compounds, or any components of the formulation, or history of significant atopy",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "893e4390-f5f2-4ea8-b4c9-95637c6e7222",
            "name": "Criterion 17",
            "text": "have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the study",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a303ef7b-d3ed-46b0-b21a-fd95075355a4",
            "name": "Criterion 18",
            "text": "any significant changes in insulin regimen and/or unstable blood glucose control within the past 3 months prior to screening as assessed by the investigator",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a5624993-81f9-4a6a-a46f-b6a507907b8e",
            "name": "Criterion 19",
            "text": "have received a total daily dose of insulin >1.2 U/kg at the time of screening",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "bc3f661e-e812-4b54-8322-c5db92895d14",
            "name": "Criterion 20",
            "text": "have poorly controlled hypertension (ie, supine systolic BP >165 mm Hg or supine diastolic BP >95 mm Hg) at screening, or a change in antihypertensive medications within 30 days prior to screening",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "08b4fa24-04cd-440a-afee-1ce71b208555",
            "name": "Criterion 21",
            "text": "have a history of pheochromocytoma (ie, adrenal gland tumor) or insulinoma",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "38ecdb92-8dbf-4213-b86a-2fd434673aaf",
            "name": "Criterion 22",
            "text": "have a history of an episode of severe hypoglycemia (as defined by an episode that required third party assistance for treatment) in the 1 month prior to screening or have a history of loss of consciousness within the last 2 years induced other than by hypoglycemia",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ddf27d26-5484-4277-aad0-84752e47f201",
            "name": "Criterion 23",
            "text": "have a history of epilepsy or seizure disorder",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "bbb8d445-cac5-4dbd-9230-fac5c83f9273",
            "name": "Criterion 24",
            "text": "have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from T1DM or T2DM), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "06b96421-9a33-44a4-b8c9-57d1ff35f3bf",
            "name": "Criterion 25",
            "text": "have known or ongoing psychiatric disorders that, in the opinion of the investigator, may preclude the patient from following and completing the protocol",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "04fcfe02-bf45-4545-81a4-ce13227ff1f0",
            "name": "Criterion 26",
            "text": "regularly use known drugs of abuse and/or show positive findings on urinary drug screening",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "8e028651-501b-4e32-b390-b756896dfce1",
            "name": "Criterion 27",
            "text": "show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies and/or antigen",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "9ff3e1ff-47db-4446-801c-950f94289618",
            "name": "Criterion 28",
            "text": "show evidence of hepatitis C and/or positive hepatitis C antibody",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ce9ae98b-7e2b-4b56-9db6-3a1ae3d67c7e",
            "name": "Criterion 29",
            "text": "show evidence of hepatitis B and/or positive hepatitis B surface antigen",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "9318d9da-5d74-44db-9fd4-c13cf143f121",
            "name": "Criterion 30",
            "text": "show evidence of syphilis and/or are positive for syphilis test",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "721ab8c4-9b5f-4608-a0ce-47411446ef09",
            "name": "Criterion 31",
            "text": "are women who are lactating",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "bb159da5-fe2b-4e42-9922-658c1ba111df",
            "name": "Criterion 32",
            "text": "use of daily systemic beta-blocker, indomethacin, warfarin, anticholinergic drugs",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "98060254-5a3c-4978-b23e-d5ee13f3da59",
            "name": "Criterion 33",
            "text": "have donated 400 mL or more blood in the last 12 weeks (males) or in the last 16 weeks (females), or any blood donation (including apheresis) within the last 4 weeks, or total volume of blood donation within 12 months is 1200 mL (males)/800 mL (females) or more at screening",
            "instanceType": "EligibilityCriterionItem"
          }
        ],
        "studyInterventions": [
          {
            "id": "8fd39ba0-7a89-42b5-8634-0641b7c27be7",
            "name": "LY900018",
            "type": {
              "id": "c99f79f7-6f1a-4814-84a8-6407f31060fc",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "fdad7360-80cf-4c77-969e-2a91a45dc367",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Nasal glucagon (LY900018) is a powder formulation of human glucagon for the rescue treatment of hypoglycemia.",
            "productIds": [
              "fa7ee7e6-d9a0-4800-82d4-3a6542bca2fa"
            ],
            "administrationIds": [
              "81e6a80d-6b45-4555-8fcb-06a100cba2ca"
            ]
          },
          {
            "id": "e16be2fc-14e5-42be-91b9-5480d69db93c",
            "name": "GlucaGen",
            "type": {
              "id": "eca95028-24c1-498b-8c80-9717f930167a",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "role": {
              "id": "c70e2a03-0a79-45a0-bf2a-4ca39a89cf33",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Intramuscular glucagon (IMG) used as an active comparator, requires reconstitution prior to administration.",
            "productIds": [
              "52e83c68-6342-4b2e-90c5-d7e3a0a7ad21"
            ],
            "administrationIds": [
              "2b4eae47-f4d6-4d84-8f35-b2d2f4a3b881"
            ]
          },
          {
            "id": "38fbb725-8654-419b-a5a7-f9e1208b8733",
            "name": "Human regular insulin",
            "type": {
              "id": "4fc7e6c0-7f91-4eeb-8b8a-72da8a2a58b4",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "7446683a-1bb9-4e6f-90d5-51ead174b24b",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Administered via IV infusion to induce hypoglycemia as part of the study procedure.",
            "productIds": [
              "d80d7dde-126b-4d1d-8a97-540c21ed69cd"
            ],
            "administrationIds": [
              "ab80af25-76cd-4d43-bc9e-e040a4121a82"
            ]
          },
          {
            "id": "91c515ec-db8b-4426-9b01-dc4812b84b75",
            "name": "Intravenous glucose",
            "type": {
              "id": "af4a5e87-7bb3-49f0-bff4-0186f75a9553",
              "code": "C54125",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Rescue Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "c1e47a96-d6ef-4b07-8c92-ec5da5ea60e3",
              "code": "C54125",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Rescue Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Administered if a patient has an insufficient response to glucagon administration, loses consciousness, or experiences symptoms of severe hypoglycemia.",
            "productIds": [
              "5fc24300-716f-4d99-b267-7bd58e92cda6"
            ],
            "administrationIds": [
              "3f65bd25-fcc9-41ab-8ccb-59bc2b632cc8"
            ]
          }
        ],
        "administrableProducts": [
          {
            "id": "fa7ee7e6-d9a0-4800-82d4-3a6542bca2fa",
            "name": "LY900018",
            "administrableDoseForm": {
              "id": "e1829d15-ca20-4d32-b136-163599018cad",
              "code": "C42970",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Powder",
              "instanceType": "Code",
              "standardCode": {
                "id": "2ba7d4f6-24ac-4102-a18d-016fb195c2cb",
                "code": "C42970",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Powder",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "961937b3-95b6-4aa6-b123-8c8849376613",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "3 mg",
            "substanceIds": [
              "a21de4d4-9195-4d6f-8411-70c4f909b881"
            ],
            "manufacturer": "Lilly"
          },
          {
            "id": "52e83c68-6342-4b2e-90c5-d7e3a0a7ad21",
            "name": "GlucaGen",
            "administrableDoseForm": {
              "id": "16b5d4c1-4d00-434b-851a-b6421622342f",
              "code": "C42945",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Injection",
              "instanceType": "Code",
              "standardCode": {
                "id": "efb8c119-de5d-4b79-8132-3912bd3882f7",
                "code": "C42945",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Injection",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "2013f163-77f9-4878-8c53-e71ffb7094c2",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "1 mg",
            "substanceIds": [
              "39416714-da9e-4bff-98eb-01232353696d"
            ],
            "manufacturer": "Novo Nordisk A/S"
          },
          {
            "id": "d80d7dde-126b-4d1d-8a97-540c21ed69cd",
            "name": "Human regular insulin",
            "administrableDoseForm": {
              "id": "1454a7b0-d657-460b-aa40-e12fd48f266a",
              "code": "C42986",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Solution",
              "instanceType": "Code",
              "standardCode": {
                "id": "4eaeb588-1e62-4811-9b02-0385fd7ac2a1",
                "code": "C42986",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Solution",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "c2dfdbed-9acc-4f5b-85b4-f1a8bedde7a5",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "0.3 U/mL",
            "substanceIds": [
              "4295d165-e6a6-41c7-ba3c-9ed52c112313"
            ]
          },
          {
            "id": "5fc24300-716f-4d99-b267-7bd58e92cda6",
            "name": "Intravenous glucose",
            "administrableDoseForm": {
              "id": "09dd5fe7-63b7-4f9d-a0ae-90b12a2bcc72",
              "code": "C42986",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Solution",
              "instanceType": "Code",
              "standardCode": {
                "id": "7e655dd7-2d02-408a-98f6-b33cc1427853",
                "code": "C42986",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Solution",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "743d94ed-1396-404b-b5fa-7ab6ad1c3e5c",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct"
          }
        ],
        "narrativeContentItems": [
          {
            "id": "47040099-fca1-45d0-8931-ec9502c92022",
            "name": "Protocol Synopsis",
            "text": "Protocol Synopsis",
            "order": 0,
            "instanceType": "NarrativeContent",
            "sectionNumber": "1",
            "sectionTitle": "Protocol Synopsis",
            "sectionType": {
              "id": "9915acfe-22a9-405a-a00a-0657b64490fc",
              "code": "Synopsis",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Synopsis",
              "instanceType": "Code"
            }
          },
          {
            "id": "a5281a46-ace2-43d7-9cba-0913e584000a",
            "name": "Schedule of Activities",
            "text": "Schedule of Activities",
            "order": 1,
            "instanceType": "NarrativeContent",
            "sectionNumber": "2",
            "sectionTitle": "Schedule of Activities",
            "sectionType": {
              "id": "170c6c99-3288-453f-8768-e8f38a302629",
              "code": "Assessments",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Assessments",
              "instanceType": "Code"
            }
          },
          {
            "id": "d56e93fe-2cd7-4418-9e94-48b3e6fd687e",
            "name": "Introduction",
            "text": "Introduction",
            "order": 2,
            "instanceType": "NarrativeContent",
            "sectionNumber": "3",
            "sectionTitle": "Introduction",
            "sectionType": {
              "id": "1d943038-0c36-477e-b37e-ea7eb7abb62c",
              "code": "Introduction",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Introduction",
              "instanceType": "Code"
            },
            "childIds": [
              "896c666f-58ea-48bc-85f9-ebb39df9f267",
              "6c0073cf-a8e3-473f-a6ce-aa6488447097",
              "83b49fa4-8f01-4cc0-8bfe-97886b6f1495"
            ]
          },
          {
            "id": "a6db5170-ebea-4695-8620-0aa66152629a",
            "name": "Objectives and Endpoints",
            "text": "Objectives and Endpoints",
            "order": 3,
            "instanceType": "NarrativeContent",
            "sectionNumber": "4",
            "sectionTitle": "Objectives and Endpoints",
            "sectionType": {
              "id": "8282018a-4319-4726-b12c-e4a695b05d81",
              "code": "Objectives",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Objectives",
              "instanceType": "Code"
            }
          },
          {
            "id": "bdeef41a-c79e-453a-be0e-ea56e6f51d17",
            "name": "Study Design",
            "text": "Study Design",
            "order": 4,
            "instanceType": "NarrativeContent",
            "sectionNumber": "5",
            "sectionTitle": "Study Design",
            "sectionType": {
              "id": "5fa91ba6-b201-4545-a9b5-9aecf5f63104",
              "code": "Study Design",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Design",
              "instanceType": "Code"
            },
            "childIds": [
              "54144314-24d8-4dca-924f-9d0410ddd66f",
              "ab0f5590-0e4c-4e7c-bbd2-d60647386527",
              "3ee75dd2-39b5-454a-874a-ce90760efce4",
              "8009dedc-9fd8-4e77-ae52-0f30d3285187",
              "34662af6-df07-4f8b-88ad-0f4a9cc981c0"
            ]
          },
          {
            "id": "e9b5b006-c486-41b4-b039-c98bbf30dc8f",
            "name": "Study Population",
            "text": "Study Population",
            "order": 5,
            "instanceType": "NarrativeContent",
            "sectionNumber": "6",
            "sectionTitle": "Study Population",
            "sectionType": {
              "id": "1c5f312a-d6ef-42ec-9542-066fa3ae9d1d",
              "code": "Study Population",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Population",
              "instanceType": "Code"
            },
            "childIds": [
              "ea81cefb-66e5-4eab-b665-e88119253b60",
              "bc16a771-9388-4b84-9691-72b65293e9e8",
              "46008fd7-09fb-4050-8ffc-4771eee119e9",
              "a39ff331-5a04-4ae5-bf9a-be10eb3437e7"
            ]
          },
          {
            "id": "cb6a648a-5968-4ebf-a579-da9b2cadedce",
            "name": "Treatment",
            "text": "Treatment",
            "order": 6,
            "instanceType": "NarrativeContent",
            "sectionNumber": "7",
            "sectionTitle": "Treatment",
            "sectionType": {
              "id": "20c5dd83-d619-4c59-b8cd-ec8a29e55916",
              "code": "Treatment",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Treatment",
              "instanceType": "Code"
            },
            "childIds": [
              "cb251280-faa8-4124-af53-fe6988557168",
              "0e244533-30d4-42a4-962c-f3e8b6d2a80c"
            ]
          },
          {
            "id": "d55a9348-b9df-47ed-98fd-e402cb9aeb3f",
            "name": "Abbreviations and Definitions",
            "text": "Abbreviations and Definitions",
            "order": 7,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 1",
            "sectionTitle": "Abbreviations and Definitions",
            "sectionType": {
              "id": "9c40cfdb-0847-41f0-abfd-e719b24be833",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "6f5c0cc6-3c57-4c8a-b6bb-5f35efa291ea",
            "name": "Clinical Laboratory Tests",
            "text": "Clinical Laboratory Tests",
            "order": 8,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 2",
            "sectionTitle": "Clinical Laboratory Tests",
            "sectionType": {
              "id": "5e484214-6f36-4f34-9abe-8276ec7596e2",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "00c91e9b-7fbe-4eca-9a5d-a96199afb565",
            "name": "Study Governance, Regulatory and Ethical Considerations",
            "text": "Study Governance, Regulatory and Ethical Considerations",
            "order": 9,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 3",
            "sectionTitle": "Study Governance, Regulatory and Ethical Considerations",
            "sectionType": {
              "id": "9ba88d86-bf50-485e-b424-aada809cec2c",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "a90350ff-f5b5-433b-a43c-58792b48661f",
            "name": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
            "text": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
            "order": 10,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 4",
            "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
            "sectionType": {
              "id": "f08545d1-076c-4f6b-955f-62decc19e670",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "9024e5d0-33fb-4c8c-ad56-7437ca3ebf41",
            "name": "Blood Sampling Summary",
            "text": "Blood Sampling Summary",
            "order": 11,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 5",
            "sectionTitle": "Blood Sampling Summary",
            "sectionType": {
              "id": "15514b4f-fec8-40c8-b59d-cbb873c10f73",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "dd61825e-15e3-4525-b126-6ceca136562a",
            "name": "Nasal and Non-nasal Score Questionnaire",
            "text": "Nasal and Non-nasal Score Questionnaire",
            "order": 12,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 6",
            "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
            "sectionType": {
              "id": "48c99283-33e1-430c-bcf5-27274faaffcb",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "e6869b87-ac34-479e-9d07-c1feca232b9e",
            "name": "Edinburgh Hypoglycemia Scale",
            "text": "Edinburgh Hypoglycemia Scale",
            "order": 13,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 7",
            "sectionTitle": "Edinburgh Hypoglycemia Scale",
            "sectionType": {
              "id": "d99181b2-bb75-436e-9580-67720752867b",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "7e2f5c5f-3b0e-4d82-b6c7-9283c00c2f5e",
            "name": "Clarke Hypoglycemia Awareness Survey",
            "text": "Clarke Hypoglycemia Awareness Survey",
            "order": 14,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 8",
            "sectionTitle": "Clarke Hypoglycemia Awareness Survey",
            "sectionType": {
              "id": "c22fdda0-ce24-49fd-92fe-3ad2921c9638",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "6cf321a7-a9cf-4998-801d-f9bd6e4af40f",
            "name": "Protocol Amendment I8R-JE-IGBJ(a) Summary A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
            "text": "Protocol Amendment I8R-JE-IGBJ(a) Summary A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
            "order": 15,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 9",
            "sectionTitle": "Protocol Amendment I8R-JE-IGBJ(a) Summary A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
            "sectionType": {
              "id": "c698fbe2-4c7f-468c-b710-ba5bb4c0bb93",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          }
        ],
        "abbreviations": [
          {
            "id": "96501a68-ca01-4c22-ae6c-5e308c35ae88",
            "abbreviatedText": "IM",
            "expandedText": "intramuscular",
            "instanceType": "Abbreviation"
          },
          {
            "id": "0fba13c3-170a-4ab8-b922-b41e64ad63ff",
            "abbreviatedText": "T1DM",
            "expandedText": "type 1 diabetes mellitus",
            "instanceType": "Abbreviation"
          },
          {
            "id": "9aad8eba-a6e3-4009-8ae9-075ff21cb935",
            "abbreviatedText": "T2DM",
            "expandedText": "type 2 diabetes mellitus",
            "instanceType": "Abbreviation"
          },
          {
            "id": "876e8dc6-03ed-4619-aa16-6297ed56bff8",
            "abbreviatedText": "PG",
            "expandedText": "plasma glucose",
            "instanceType": "Abbreviation"
          },
          {
            "id": "cdd2ceee-833d-464a-ac4a-f8846a707cb8",
            "abbreviatedText": "IMG",
            "expandedText": "intramuscular glucagon",
            "instanceType": "Abbreviation"
          },
          {
            "id": "29ed48fa-2954-4f01-b11b-0bf81a5ee28e",
            "abbreviatedText": "AE",
            "expandedText": "adverse event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "17d76f74-35c1-4c6c-974b-3826a774f2d9",
            "abbreviatedText": "AUC",
            "expandedText": "area under the concentration versus time curve",
            "instanceType": "Abbreviation"
          },
          {
            "id": "7e758c9a-3a87-45ea-b70f-14bf6c4ccf23",
            "abbreviatedText": "BGmax",
            "expandedText": "maximal plasma glucose concentration",
            "instanceType": "Abbreviation"
          },
          {
            "id": "589518c1-1ddc-4082-ba54-4cf667a9d910",
            "abbreviatedText": "Cmax",
            "expandedText": "maximal concentration",
            "instanceType": "Abbreviation"
          },
          {
            "id": "9d5825c7-d0f5-49a5-bd63-cfadac81409b",
            "abbreviatedText": "PD",
            "expandedText": "pharmacodynamics",
            "instanceType": "Abbreviation"
          },
          {
            "id": "116cad03-5d68-4291-99c5-32dd9973774e",
            "abbreviatedText": "PK",
            "expandedText": "pharmacokinetics",
            "instanceType": "Abbreviation"
          },
          {
            "id": "19fd5192-04e9-4eb2-8038-adea2d859bfd",
            "abbreviatedText": "SAE",
            "expandedText": "serious adverse event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2429befd-8c95-4d2c-ada6-b6406cdb5f94",
            "abbreviatedText": "TEAE",
            "expandedText": "treatment-emergent adverse event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "d04a7ca9-4d79-426d-a581-b3d0902ad8a7",
            "abbreviatedText": "Tmax",
            "expandedText": "time to maximal concentration",
            "instanceType": "Abbreviation"
          }
        ],
        "amendments": [
          {
            "id": "4907393b-8393-4bf4-91b8-8ff7cbf842d2",
            "number": "a",
            "name": "Amendment a",
            "scope": {
              "id": "c4ba1051-b26d-40de-90b1-3a9f105ba675",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "bc8b8702-faeb-4534-a2f1-81b8a81a768f",
              "code": {
                "id": "c08dfaee-9d26-4adc-a69d-bf3a29e625bb",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "e639f53a-5ac3-447d-bf8a-cc0b305ff84e",
                "type": {
                  "id": "4f79716c-a6ec-499e-94dc-bde1f7fea2f0",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The summary for this amendment is listed in Appendix 9, which was not provided in the source document.",
            "effectiveDate": "2017-12-05",
            "previousVersion": "Original Protocol",
            "newVersion": "a"
          }
        ],
        "medicalDevices": [
          {
            "id": "37866794-178a-4f24-b381-87ad9a2f4e84",
            "name": "Nasal Dosing Device",
            "instanceType": "MedicalDevice",
            "label": "Nasal Glucagon Device",
            "description": "A user-friendly, single-use, nasal dosing device that delivers 3 mg glucagon powder for absorption through the nasal mucosa.",
            "deviceType": {
              "id": "ce95d5bb-67f3-49db-b803-09052d2fa424",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "85150ce4-beaf-478f-83a5-9a1785f64812",
            "name": "Syringe and Needle",
            "instanceType": "MedicalDevice",
            "label": "Syringe/Needle",
            "description": "Used for intramuscular (IM) injection of reconstituted glucagon powder.",
            "deviceType": {
              "id": "cedad441-6102-4dae-b7c9-13b82a9c5ae8",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "e91a1067-483c-42a9-a80d-6502748fb58e",
            "name": "Bedside Glucose Monitor",
            "instanceType": "MedicalDevice",
            "label": "Glucometer",
            "description": "Device used for bedside plasma glucose (PG) monitoring for safety.",
            "deviceType": {
              "id": "0c4b3b08-4d19-48f5-9663-84847d3c771a",
              "code": "Monitoring Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Monitoring Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "8f37d175-e615-4ed7-9865-f0c5f6415291",
            "name": "12-lead Electrocardiogram Machine",
            "instanceType": "MedicalDevice",
            "label": "ECG Machine",
            "description": "Device used to perform single and triplicate 12-lead ECGs.",
            "deviceType": {
              "id": "31e4ae3d-227d-4069-8cc2-e26bf001ef29",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "88248be6-4a65-4c97-b1ff-e31853364560",
            "name": "Continuous Subcutaneous Insulin Infusion Pump",
            "instanceType": "MedicalDevice",
            "label": "CSII Pump",
            "description": "An insulin pump used for continuous subcutaneous insulin infusion as part of patients' regular therapy.",
            "deviceType": {
              "id": "82be8ce0-f469-4972-8505-387eadbec27e",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "03c64004-45df-468b-87f9-7e489be43314",
            "name": "IV Infusion System",
            "instanceType": "MedicalDevice",
            "label": "IV Pump",
            "description": "System used for the intravenous infusion of insulin to induce hypoglycemia.",
            "deviceType": {
              "id": "c2d09fe1-aec3-4e71-bc41-fda0774efcbf",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            }
          }
        ],
        "rationale": "Protocol version"
      }
    ],
    "name": "A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus"
  },
  "administrations": [
    {
      "id": "81e6a80d-6b45-4555-8fcb-06a100cba2ca",
      "name": "LY900018 3 mg single dose",
      "instanceType": "Administration",
      "dose": "3 mg",
      "doseFrequency": "Single dose",
      "route": {
        "id": "02f07b03-9287-443d-b168-561939786127",
        "code": "Intranasal",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intranasal",
        "instanceType": "Code"
      },
      "duration": "Single administration per treatment period"
    },
    {
      "id": "2b4eae47-f4d6-4d84-8f35-b2d2f4a3b881",
      "name": "GlucaGen 1 mg single dose",
      "instanceType": "Administration",
      "dose": "1 mg",
      "doseFrequency": "Single dose",
      "route": {
        "id": "9c8fbdb7-75dc-4e28-8b2b-bea0fcca4455",
        "code": "Intramuscular",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intramuscular",
        "instanceType": "Code"
      },
      "duration": "Single administration per treatment period"
    },
    {
      "id": "ab80af25-76cd-4d43-bc9e-e040a4121a82",
      "name": "Human regular insulin infusion",
      "instanceType": "Administration",
      "dose": "2 mU/kg/min, adjustable up to 3 mU/kg/min for T1DM or 4 mU/kg/min for T2DM",
      "doseFrequency": "Continuous infusion",
      "route": {
        "id": "d22a25ec-905a-4fc2-bf9d-44f8807b60e2",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Until bedside plasma glucose is <60 mg/dL, for a maximum of 4 hours"
    },
    {
      "id": "3f65bd25-fcc9-41ab-8ccb-59bc2b632cc8",
      "name": "Intravenous glucose rescue",
      "instanceType": "Administration",
      "dose": "As deemed clinically necessary",
      "doseFrequency": "As needed",
      "route": {
        "id": "6e4c850c-49ed-4034-afe8-be28ed344e14",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "As needed for insufficient response to glucagon"
    }
  ],
  "substances": [
    {
      "id": "a21de4d4-9195-4d6f-8411-70c4f909b881",
      "name": "glucagon",
      "instanceType": "Substance",
      "description": "Synthetic single-chain, 29-amino-acid polypeptide identical to human glucagon. Active ingredient in LY900018 and GlucaGen."
    },
    {
      "id": "39416714-da9e-4bff-98eb-01232353696d",
      "name": "human regular insulin",
      "instanceType": "Substance",
      "description": "Active substance used to induce hypoglycemia."
    },
    {
      "id": "4295d165-e6a6-41c7-ba3c-9ed52c112313",
      "name": "glucose",
      "instanceType": "Substance",
      "description": "Active substance in the rescue medication."
    }
  ],
  "studyDefinitionDocument": {
    "id": "9edc2d60-2d14-4f9f-a55c-66d9c5aada3d",
    "name": "A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "I8R-JE-IGBJ(a)",
    "contentIds": [
      "47040099-fca1-45d0-8931-ec9502c92022",
      "a5281a46-ace2-43d7-9cba-0913e584000a",
      "d56e93fe-2cd7-4418-9e94-48b3e6fd687e",
      "a6db5170-ebea-4695-8620-0aa66152629a",
      "bdeef41a-c79e-453a-be0e-ea56e6f51d17",
      "e9b5b006-c486-41b4-b039-c98bbf30dc8f",
      "cb6a648a-5968-4ebf-a579-da9b2cadedce",
      "d55a9348-b9df-47ed-98fd-e402cb9aeb3f",
      "6f5c0cc6-3c57-4c8a-b6bb-5f35efa291ea",
      "00c91e9b-7fbe-4eca-9a5d-a96199afb565",
      "a90350ff-f5b5-433b-a43c-58792b48661f",
      "9024e5d0-33fb-4c8c-ad56-7437ca3ebf41",
      "dd61825e-15e3-4525-b126-6ceca136562a",
      "e6869b87-ac34-479e-9d07-c1feca232b9e",
      "7e2f5c5f-3b0e-4d82-b6c7-9283c00c2f5e",
      "6cf321a7-a9cf-4998-801d-f9bd6e4af40f"
    ]
  },
  "geographicScope": {
    "id": "b8fb23fd-e3bc-49f9-be7c-2b72b353a18f",
    "name": "Study Geographic Scope",
    "scopeType": "Single-country",
    "instanceType": "GeographicScope",
    "countryIds": [
      "e35c553c-7078-4aab-9bd6-7e2be0e1c3ce"
    ]
  },
  "countries": [
    {
      "id": "e35c553c-7078-4aab-9bd6-7e2be0e1c3ce",
      "name": "Japan",
      "instanceType": "Country",
      "code": "JP"
    }
  ],
  "ingredients": [
    {
      "id": "e5ecdaa0-5175-4798-9431-4f3365ee7ab0",
      "name": "Glucagon",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "970a1536-c27f-4dae-af9f-d8b8c63879db",
      "name": "Insulin",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "c50ea5f8-89ad-4d49-81e3-3b7d638367db",
      "name": "Insulin Glargine",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "1d5022ca-204a-4342-9cd1-7e46606ef82f",
      "name": "Insulin Degludec",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "53ef3d62-74d6-4538-ae52-86b24c7911e0",
      "name": "Insulin Lispro",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "2af0fb48-6d6e-49ad-aa6b-025ef8791f96",
      "name": "Insulin Aspart",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "c7df07f2-9655-4cdb-a5d9-f421cd10717b",
      "name": "Insulin Glulisine",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "f6ef9671-56fb-48b2-a012-cec8ec2ca439",
      "name": "Glucose",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "12248da7-0a68-410c-9570-2908b85ff204",
      "name": "Metformin",
      "role": "Active",
      "instanceType": "Ingredient"
    }
  ],
  "strengths": [
    {
      "id": "83b7e8a4-d334-4ec2-a49f-d9a886e4cfa8",
      "instanceType": "Strength",
      "value": 3,
      "unit": "mg",
      "numerator": {
        "value": 3,
        "unit": "mg"
      }
    },
    {
      "id": "04c0eb10-b59a-4fa3-ae0e-5f6b6ac22ee0",
      "instanceType": "Strength",
      "value": 1,
      "unit": "mg",
      "numerator": {
        "value": 1,
        "unit": "mg"
      }
    },
    {
      "id": "76f0daaf-63a5-4ac8-aac5-6f18192901a2",
      "instanceType": "Strength",
      "value": 100,
      "unit": "U/mL",
      "numerator": {
        "value": 100,
        "unit": "U"
      },
      "denominator": {
        "value": 1,
        "unit": "mL"
      }
    },
    {
      "id": "405f01d9-5bfd-403d-a722-1e65292cd290",
      "instanceType": "Strength",
      "value": 300,
      "unit": "U/mL",
      "numerator": {
        "value": 300,
        "unit": "U"
      },
      "denominator": {
        "value": 1,
        "unit": "mL"
      }
    }
  ],
  "documentContentReferences": [
    {
      "id": "cdbec225-162f-4516-bf9a-76715c520a09",
      "name": "Reference to Clinical Laboratory Tests Appendix",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 2",
      "sectionTitle": "Clinical Laboratory Tests",
      "description": "Reference from the Schedule of Activities (Clinical Lab Tests row) to Appendix 2 for details."
    },
    {
      "id": "4a7fab98-1b46-4638-84fe-ce4076f9761e",
      "name": "Reference to Schedule of Activities",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "2",
      "sectionTitle": "Schedule of Activities",
      "description": "Reference from Section 9 (Study Assessments and Procedures) to Section 2 for the timing of study procedures."
    },
    {
      "id": "05abd97c-7df1-4ff9-b5c2-37548612e5f4",
      "name": "Reference to Laboratory Tests Appendix",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 2",
      "sectionTitle": "Clinical Laboratory Tests",
      "description": "Reference from Section 9 (Study Assessments and Procedures) to Appendix 2 for the list of laboratory tests."
    },
    {
      "id": "0b02a887-3f55-46cd-99ff-47b0f5033950",
      "name": "Reference to Blood Sampling Summary Appendix",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 5",
      "sectionTitle": "Blood Sampling Summary",
      "description": "Reference from Section 9 (Study Assessments and Procedures) to Appendix 5 for a summary of invasive samples."
    },
    {
      "id": "04a737d7-2e81-4fec-ae4f-c59ac1c45fce",
      "name": "Reference to Post Glucagon Administration Procedures",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "9.2.3",
      "sectionTitle": "Post Glucagon Administration",
      "description": "Reference from Section 9.1 (Efficacy Assessments) to Section 9.2.3 for details on plasma glucose level measurement."
    },
    {
      "id": "7ab387d0-6ce4-4982-9489-444fcff5b409",
      "name": "Reference to Edinburgh Hypoglycemia Scale Appendix",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 7",
      "sectionTitle": "Edinburgh Hypoglycemia Scale",
      "description": "Reference from Section 9.1.3 (Exploratory Efficacy Assessments) to Appendix 7 for the self-reported assessment tool."
    },
    {
      "id": "51d96b72-67bc-4365-bf1e-2b4eb81343ce",
      "name": "Reference to Schedule of Activities for Assessment Timing",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "2",
      "sectionTitle": "Schedule of Activities",
      "description": "Reference from Section 9.1.3 (Exploratory Efficacy Assessments) to Section 2 for the timing of hypoglycemia symptom assessments."
    },
    {
      "id": "9a84b1a6-2156-40b3-9751-d0ceccbe313b",
      "name": "Reference to Clarke Hypoglycemia Awareness Survey Appendix",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 8",
      "sectionTitle": "Clarke Hypoglycemia Awareness Survey",
      "description": "Reference from Section 9.1.3 (Exploratory Efficacy Assessments) to Appendix 8 for the self-report assessment tool."
    },
    {
      "id": "c1446ee3-922f-49d9-aa2b-67c4c75bd64f",
      "name": "Reference to Schedule of Activities for Blood Sampling",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "2",
      "sectionTitle": "Schedule of Activities",
      "description": "Reference from Section 9.2.1 (Insulin-induced Hypoglycemia) to the Schedule of Activities for blood sample collection times."
    },
    {
      "id": "dccc714f-122a-4bbe-be0c-6a6ae8b04150",
      "name": "Reference to Treatment Details",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7",
      "sectionTitle": "Treatment",
      "description": "Reference from Section 9.2.2 (Glucagon Administration) to Section 7 for details regarding treatments."
    },
    {
      "id": "e11d5125-f295-45b6-843a-1706036fb33f",
      "name": "Reference to Nasal and Non-nasal Score Questionnaire Appendix",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 6",
      "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
      "description": "Reference from Section 9.2.2.1 (Nasal LY900018 Administration) to Appendix 6 for a copy of the questionnaire."
    },
    {
      "id": "d0d9fae4-1ec5-4205-b984-2aaf7500a7b7",
      "name": "Reference to Adverse Event Monitoring Questionnaires",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 6",
      "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
      "description": "Reference from Section 9.3.1.2 (Adverse Event Monitoring with a Systematic Questionnaire) to Appendix 6."
    },
    {
      "id": "fcc92121-4d07-44e7-acb2-9ff5708dd50e",
      "name": "Reference to Adverse Event Monitoring Questionnaires",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 7",
      "sectionTitle": "Edinburgh Hypoglycemia Scale",
      "description": "Reference from Section 9.3.1.2 (Adverse Event Monitoring with a Systematic Questionnaire) to Appendix 7."
    },
    {
      "id": "339c4c99-ebc0-4b1a-bc16-f247589725d8",
      "name": "Reference to Schedule of Activities for Safety Assessments",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "2",
      "sectionTitle": "Schedule of Activities",
      "description": "Reference from Section 9.5 (Safety) to Section 2 for the timing of laboratory tests, vital signs, and ECGs."
    },
    {
      "id": "b071d3e6-9d3e-44ad-bd52-fff31d3dcbdc",
      "name": "Reference to Hepatic Monitoring Tests Appendix",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 4",
      "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
      "description": "Reference from Section 9.5.5.2 (Hepatic Safety) to Appendix 4 for the list of liver tests to be repeated upon abnormality."
    }
  ],
  "commentAnnotations": [
    {
      "id": "98c59446-0ac0-4418-b292-84678d797aac",
      "text": "Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Confidential Information",
      "pageNumber": 2
    },
    {
      "id": "a785e03d-1ce2-40e9-ae1e-b592d14f5e80",
      "text": "Patients do not need to fast for samples at screening or follow-up. At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 15
    },
    {
      "id": "977bc421-de4d-47f1-816e-556b06b881c8",
      "text": "Serum pregnancy test will be performed at screening. Urine pregnancy test will be performed at every admission period and follow-up visit if applicable.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 15
    },
    {
      "id": "c2bda18b-ba49-4612-8fac-a3023f98294b",
      "text": "If an SAE occurs after signing informed consent, but prior to receiving investigational product, AND is considered reasonably possibly related to a study procedure then it MUST be reported.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "9.3.1 Serious Adverse Events",
      "pageNumber": 39
    },
    {
      "id": "58d9255f-79d0-49e8-84ad-dbeb590af5fa",
      "text": "Only severe hypoglycemic episodes will be reported separately as AEs. If a hypoglycemic event meets the criteria of severe, it needs to be recorded as serious in the CRF (that is, recorded as an SAE).",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "9.5.5.1 Hypoglycemic Event Reporting",
      "pageNumber": 43
    }
  ],
  "studyDefinitionDocumentVersions": [
    {
      "id": "fb96accd-4768-4e32-9608-8814f8a442c6",
      "versionNumber": "I8R-JE-IGBJ(a)",
      "status": "Approved",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2017-12-05",
      "description": "Protocol Amendment (a) to protocol I8R-JE-IGBJ. The base protocol was approved on 26 October 2017.",
      "amendmentNumber": "a"
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "complete"
  }
}